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Acute limb compartment syndrome (ACS), a potentially devastating 
complication of musculoskeletal trauma, results in muscle necrosis and cell death. 
Ischemia and inflammation both contribute to microvascular dysfunction and 
parenchymal injury. Currently, surgical fasciotomy remains the only first-line 
treatment. 
Systemic application of carbon monoxide-releasing molecule-3 (CORM-3) 
in animal models of ACS has shown benefits when given in conjunction with 
fasciotomy; however, CORM-3 without fasciotomy has never been tested. The 
purpose of this thesis was to assess the effects of CORM-3 in ACS without surgical 
intervention. 
Twenty-nine male adult Wistar rats were used to test the effects of CORM-
3. Microvascular perfusion, tissue injury, and inflammatory response were 
measured at 24, 48, and 72 hours following intracompartmental pressure elevation 
and CORM-3 injection.  
The results demonstrated partially restored microvascular perfusion, 
significantly reduced tissue injury, and significantly  diminished leukocyte 
activation (inflammation), indicating the potential of CORM-3 as a pharmacological 
agent in the treatment for ACS. 
 
Keywords: acute compartment syndrome; elevated intracompartmental 
pressure; carbon monoxide; CORM-3; fasciotomy; microvascular 




SUMMARY FOR LAY AUDIENCE 
 
Acute limb compartment syndrome (ACS) is a potentially devastating 
complication of limb trauma resulting in muscle and cell death. Lack of blood flow 
and white blood cell activation both contribute to vessel dysfunction and tissue 
injury. The treatment gold standard is an emergency surgery to relieve the tissue 
pressure.  
Injection of carbon monoxide-releasing molecule-3 (CORM-3), a substance 
that gives off carbon monoxide, in animal models of ACS has shown benefits when 
given together with surgery; however, CORM-3 without surgery has never been 
tested. Therefore, the purpose of this thesis was to assess the effects of CORM-3 
in ACS without surgical intervention. 
Twenty-nine male adult Wistar rats were used to test CORM-3. Tissue 
perfusion, injury, and white blood cell response were measured at 24, 48, and 72 
hours following tissue pressure elevation and CORM-3 injection. 
Our results demonstrated that CORM-3 injection without surgery improved 
perfusion, reduced tissue injury, and diminished inflammation, indicating its 
potential in prolonging the surgical window and its use as a pharmacological 
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CHAPTER 1:  INTRODUCTION AND LITERATURE REVIEW 
 
1.1 ACUTE COMPARTMENT SYNDROME 
Acute compartment syndrome (ACS) in musculoskeletal trauma is a limb-
threatening and, potentially, life-threatening injury. Without prompt surgical 
intervention, the elevation of pressure within a closed osseofascial compartment 
leads to tissue ischemia, myonecrosis, and nerve injury (McMillan et al. 2019; 
Mortensen et al. 2020; Schmidt 2017; von Keudell et al. 2015). The 
microvascular compromise that results in a lack of oxygen and nutrient delivery 
to the tissues then leads to cellular anoxia and cell death. Ultimately, this can 
cause severe functional impairment in extremity function, potential loss of limb, 
and even patient death. Although multiple therapeutic agents have been 
proposed, the treatment gold standard remains fasciotomy. However, the 
surgical window for the procedure is quite narrow before permanent damage 
develops (Guo et al. 2019; Mubarak & Hargens 1983). Risk factors for delayed 
diagnosis of ACS reported in the literature include poor communication between 
physicians, failure of early recognition of signs and symptoms, neurological 
injuries, altered levels of consciousness, children, and patient-controlled or 
regional anaesthetics (Bhattacharyya & Vrahas 2004; Garner et al. 2014; 





1.2 ACS: A DIAGNOSTIC CHALLENGE 
1.2.1 Aetiologies 
There are numerous causes of increased compartmental pressures in the 
limbs. They can be divided into traumatic injuries, such as fractures, soft-tissue 
trauma without fracture, and penetrating trauma; vascular injuries, such as 
arterial/venous injuries, intracompartmental bleeding, reperfusion injuries 
following ischemia; soft tissue injuries, such as burns, crush injuries, hematomas, 
animal bites; iatrogenic causes including, but not limited to, tight casts, 
constrictive dressings, prolonged lithotomy position (flexion, elevation, and 
abduction of the leg) during orthopaedic surgery, intravenous drug use, 
tourniquet application, and anticoagulation (Gourgiotis et al. 2007; Olson & 
Glasgow 2005). Reported rare causes of ACS include hypothyroidism, diabetes, 
vascular abnormalities, nephrotic syndrome, statins, and ganglion cysts of the 
proximal tibiofibular joint (Chautems et al. 1997; Flamini et al. 2008). Although 
ACS can occur in the arm, hand, thorax, abdomen, buttock, thigh, foot, 
paraspinal muscles, and even in the ocular orbit, it is most commonly seen 
following injuries to the lower leg and forearm (Elliott & Johnstone 2003; Garner 
et al. 2014; McCallum et al. 2019; Rupprecht et al. 2019).  
Bone fractures are the most common cause of ACS when compared to 
non-fracture aetiologies, and most commonly occur following tibial shaft fractures 
(Elliott & Johnstone 2003; Garner et al. 2014; McQueen et al. 2000; von Keudell 
et al. 2015). In a retrospective study, McQueen et al. (2000) found that tibial 




followed by distal radius fractures with nearly 10% of cases. Nonetheless, 23.2% 
of ACS patients were a result of soft-tissue trauma without fracture. Risk 
stratification demonstrated that men under the age of 35 are at greatest risk of 
developing ACS following injury (McQueen et al. 2000). 
 
1.2.2 Clinical Findings  
Making the diagnosis of ACS is a subject of much debate. It relies on 
clinical acumen and monitoring. Intracompartmental pressure (ICP) monitoring is 
often used when the diagnosis is equivocal; however, there are no standardized 
guidelines for its use (Garner et al. 2014; Mabvuure et al. 2012). Furthermore, 
the quality and timing of symptoms can vary between injuries and patients. 
Studies have even suggested that muscle damage can occur before the 
diagnosis of ACS becomes evident (Frink et al. 2010; Nudel et al. 2016; 
Vaillancourt et al. 2004). 
Classically, the five Ps (pain, pallor, pulselessness, paralysis, and 
paraesthesia) mnemonic has been used as a diagnostic tool for ACS (Donaldson 
et al. 2014; Gourgiotis et al. 2007). However, some authors have contended that 
they are unreliable. Von Keudell et al. (2015) argue that these represent arterial 
ischemia rather than increased compartment pressures.  Furthermore, given that 
ACS is a dynamic process, the progression of symptoms can be variable (von 
Keudell et al. 2015). 
Mubarak and colleagues (1978) found that swelling and palpable 




however, they are not diagnostic of ACS. They also found that pain with passive 
stretch was subjective and unreliable, given that it could be a result of the 
traumatic injury rather than ischemia (Mubarak et al. 1978). Furthermore, 
Rorabeck and Macnab (1976) found that hypoesthesia and anaesthesia were the 
last clinical findings to develop (Rorabeck & Macnab 1976). Meanwhile, Ulmer 
(2002) showed that pain, pain with passive stretch, paraesthesia, and paresis are 
more useful in ruling out the diagnosis of ACS in the absence of these symptoms 
rather than making the diagnosis when they are present. He found that the 
individual sensitivities of each symptom ranged from 13% to 19%, whereas their 
positive predictive value ranged from 11% to 15%. Meanwhile, both their 
specificities and negative predictive values ranged between 97% and 98%. 
Nonetheless, in patients at risk of ACS, he demonstrated that the odds of 
diagnosing ACS increase with an increasing number of symptoms present; 19% 
to 26% with one clinical finding, 68%, 93%, and 98% with two, three, and four 
clinical findings respectively (Ulmer 2002). 
Heavy reliance on the five Ps can be misleading: pain out of proportion 
and pain with passive stretch are important early clinical signs and most reliable 
indicators in the diagnosis of ACS (Donaldson et al. 2014; Guo et al. 2019; von 
Keudell et al. 2015). However, they can be confounded by the nature of the 
injury(ies) suffered, analgesics, altered levels of consciousness, being 
uncooperative or unconscious, and pain tolerance (Garner et al. 2014; 
Mortensen et al. 2020). Serial and careful examinations thus become crucial.  




considered late signs of persistent ischemia. Paraesthesia and muscle weakness 
can be a result of the injury itself rather than ACS. However, if true weakness is 
detected, then this could potentially indicate permanent muscle damage (Elliott & 
Johnstone 2003). Pulselessness is almost only noted in the very late stages of 
ACS. Tense compartments and increasing analgesic requirements are also 
important clinical signs that should increase the index of suspicion and must not 
be neglected (Garner et al. 2014; Matsen 1975; Mubarak et al. 1978). 
 
1.2.3 Use of Compartment Pressure Monitoring 
The concept of compartment pressure monitoring was first introduced by 
Whiteside and colleagues in 1975. Proper technique is critical: monitoring should 
be done within five centimetres from the zone of injury, and multiple pressure 
readings should be done rather than relying on one measurement (Heckman et 
al. 1994; Raza & Mahapatra 2015; Whitesides et al. 1975). Compartment 
pressure measurement should also be performed in all compartments of the 
extremity involved, to avoid missing ACS in adjacent compartments (Erdos et al. 
2011; Nudel et al. 2016; Whitesides & Heckman 1996). Needle misplacement, 
faulty monitoring systems, and operator experience can all affect pressure 
reading (McLaughlin et al. 2014). 
Commercial pressure monitoring systems, such as the Stryker Intra-
Compartmental Pressure Monitor System (Stryker Instruments, Kalamazoo, MI) 
or the Synthes Electronic Pressure Transducer (Synthes USA, Paoli, PA) are 




monitoring is often performed using simple hospital equipment (Pechar & Lyons 
2016; Raza & Mahapatra 2015). These include the simple needle manometry, 
wick catheter, slit catheter, central venous manometer, side-ported needle 
technique, fibreoptic transducer, and infusion technique (Gourgiotis et al. 2007; 
McLaughlin et al. 2014).  
The routine use of ICP monitoring and the threshold for fasciotomy remain 
controversial. While previous authors have advocated for absolute pressures of 
greater than 30mmHg (Mubarak et al. 1978), the more recent literature favours 
the Δp value of less than 30mmHg (McQueen et al. 2000). The Δp is a 
measurement of the difference between the diastolic blood pressure and the 
intramuscular pressure. Thus, a value below 30mmHg suggests inadequate 
perfusion. A growing body of literature supports the role of blood pressure in the 
role of ICP monitoring, given that tissue perfusion and consequent viability are 
dependent on blood pressure (Gourgiotis et al. 2007; Whitesides et al. 1975). In 
patients with tibial fractures, McQueen and Court-Brown (1996) demonstrated 
that upwards of 43% of patients would have undergone unnecessary 
fasciotomies had they used ICP measurement alone (McQueen & Court-Brown 
1996). 
It has been demonstrated that routine compartment pressure monitoring 
can lead to unnecessary fasciotomies in the alert, oriented, and cognitively sound 
patient (Guo et al. 2019; Janzing & Broos 2001; Tiwari et al. 2002). In a 
prospective study of patients with tibial fractures, Janzing and Boos (2001) 




fasciotomy or having residual physical exam symptoms consistent with 
compartment syndrome 12 months after injury) with patients without ACS (i.e. 
those who did not undergo fasciotomy and having no residual symptoms 12 
months after injury). The data revealed that unnecessary fasciotomies would 
have been performed in 6.2%, 3.1%, and 2.1% of patients based on symptoms 
alone, absolute ICP >30mmg, and Δp <30mmHg, respectively. Meanwhile, if 
decision to fasciotomy were based on ICP monitoring alone, missed ACS would 
have been found in 47.4% and 29.0% of patients based on absolute ICP 
>30mmg and Δp <30mmHg, respectively. Sensitivity and specificity for 
diagnosing ACS was 0.67 and 0.89, respectively, based on symptoms alone; 
0.83 and 0.65, respectively, based on ICP >30mmHg; 0.89 and 0.65, 
respectively, based on Δp <30 mmHg (Janzing & Broos 2001). In another study 
of patients with lower extremity injuries but no fasciotomy, 18 out of 19 patients 
had at least one ICP reading >30mmHg, with 12 patients exceeding 45mmHg 
and 16 patients with at least one Δp measurement of <30mmHg, without any 
clinical evidence of ACS (Prayson et al. 2006). A mathematical and quantitative 
analysis of ACS was also performed, arguing that even though monitoring may 
be beneficial, it is not yet fully reliable, given the non-uniform pressure 
distribution in the compartments and that permanent damage to the soft tissues 
can occasionally occur even before the onset of ACS symptoms (Nudel et al. 
2016). Therefore, ICP measurement is recommended as an adjunct, rather than 




Some authors have advocated for continuous ICP monitoring in patients at 
risk of ACS, arguing that it may detect it early, before the onset of clinical 
symptoms, hence reduce time to fasciotomy. This type of monitoring can be 
carried out by connecting the compartment catheter to an arterial line transducer. 
However, obtaining precise measurements can be technically challenging and 
has a learning curve associated with it (Matsen et al. 1976; McLaughlin et al. 
2014; McQueen & Court-Brown 1996; von Keudell et al. 2015). In a review of 
patients with a tibial fracture in which their compartment pressures were 
continuously monitored coupled with careful clinical examination did not lead to 
an increase in the rate of unnecessary fasciotomies (Al-Dadah et al. 2008). 
There is no question regarding the benefit of using ICP monitoring in 
patients with risk factors that could delay the diagnosis of ACS. These include 
young children, intoxicated patients, patients with equivocal symptoms or altered 
levels of consciousness, patients with nerve injuries, use of epidural anaesthesia 
or nerve block, polytrauma patients, and high-energy injuries (Janzing & Broos 
2001; McQueen et al. 2000). 
 
1.2.4 Alternative Diagnostic Tools 
Other proposed diagnostic tools for ACS include intramuscular oxygen 
partial pressure monitoring (Doro et al. 2014; Weick et al. 2016), near-infrared 
spectroscopy (NIRS) (Mancini et al. 1994; Shuler et al. 2011), monitoring 
localized perfusion using ultrasound or laser Doppler (Abraham et al. 1998; 




2014). In a canine model of ACS, oxygen partial pressure of <30mmHg was 
reported to have a 100% sensitivity and a 100% specificity as a diagnostic tool. 
In addition, intramuscular glucose concentrations of <97mg/dL had 100% 
sensitivity and 75% specificity (Doro et al. 2014). Although the data looks 
promising, these are still in the experimental phase in human adults. 
NIRS has been proposed and has gained more traction in recent years. Its 
proponents explain that blood flow should increase at the site of injury. A 
decrease or absence of blood flow could be used as a diagnostic tool for ACS 
and could be used as a continuous monitoring device (McMillan et al. 2019; 
Shuler et al. 2011). However, a recent study revealed poor reliability in patients 
with lower leg injuries, as well as a high number of erroneous NIRS readings 
(Schmidt et al. 2018).  
Magnetic resonance imaging has limited use in the early acute setting, as 
the swelling and edema are not differentiated between early signs of ACS or from 
the injury itself. It can, nonetheless, confirm ACS once the diagnosis is 
established. However, at that point, a significant delay in the treatment would 
occur (Mabvuure et al. 2012). 
 
1.2.5 Missed or Delayed Diagnosis 
Patients may also present with variable findings leading to missed or 
delayed diagnosis of ACS. Risk factors include patient-controlled or regional 
anaesthetics, poor communication between physicians, small children, failure of 




of consciousness (Erdos et al. 2011; Garner et al. 2014; Mortensen et al. 2020). 
The use of compartment pressure monitoring is highly recommended for patients 
with any risk factor for potential ACS; the lack of monitoring in high-risk patients 
is a common cause of missed ACS (Al-Dadah et al. 2008; Garner et al. 2014; 
McLaughlin et al. 2014). 
A case report by Wright et al. (2011) described a 39-year-old male with a 
crush injury to the left lower leg, leading to a minimally displaced fracture of the 
fibular head. The patient was noted to have absent sensory function over the 
dorsal first web space (associated with a foot drop), an absent active extension 
of the great toe (extensor hallucis longus), as well as a firm anterior compartment 
to palpation. At the same time, very little pain and no significant pain to passive 
stretch were noted, with distal pulses palpable and normal. Following fasciotomy, 
the patient quickly started regaining his sensory and motor functions. In his case, 
the ACS presented in the form of isolated peroneal palsy and an anterior 
compartment under great pressure (Wright et al. 2011). 
Additional case reports described patients who were given patient-
controlled analgesia (PCA) following tibial intramedullary nail for tibial shaft 
fracture (Harrington et al. 2000; O’Sullivan et al. 2002). The PCA masked the 
pain, delaying the diagnosis of post-operative ACS. While one patient underwent 
fasciotomy of the lower leg with subsequent closure and no long-term sequelae, 
another patient ultimately required a below-knee amputation of the leg 




 A study conducted by Hope and McQueen (2004) that compared patients 
with ACS following fracture and those in the absence of fracture revealed a 13:1 
male-to-female ratio in ACS following fracture compared to a 5:1 ratio in ACS 
without fracture. The patients without fracture were found to be significantly older 
and with more known medical comorbidities. Consequently, the time from 
admission to fasciotomy in the non-fracture related patients was delayed, on 
average, by more than 12 hours, leading to a significantly greater number of 
patients with muscle necrosis, compared to those in the fracture group (Hope & 
McQueen 2004). 
The diagnosis of ACS in young children can also pose challenges due to 
communication difficulties. A case series of patients aged 2 to 18 years revealed 
a mean time from admission to fasciotomy greater than 27 hours (Erdos et al. 
2011). Thus, careful serial examination and clinical vigilance to any potential 
signs of ACS are critical.  
Missed or delayed diagnosis of ACS can have serious consequences. 
Care must be taken to monitor for signs of shock, renal failure, acidosis, 
hypotension, hyperkalaemia, and hypocalcaemia (Guo et al. 2019). Depending 
on the amount of muscle(s) involved, missed ACS can lead to ischemic 
contractures, secondary deformity, permanent neuromuscular deficits, sensory 
deficits, limb dysfunction, infections especially gram-negative sepsis, amputation, 





Myonecrosis puts patients at high risk of myoglobinuria due to myoglobin 
released in the systemic circulation accumulating in the distal convoluted tubules 
in the kidneys, leading to acute renal failure requiring aggressive fluid hydration 
(Donaldson et al. 2014; Mabvuure et al. 2012; Whitesides & Heckman 1996). In 
severe cases of metabolic acidosis, hyperkalaemia, and renal failure, 
debridement of necrotic muscles is often indicated to prevent and minimize 
systemic failure as well as metabolic complications (von Keudell et al. 2015). 
 
1.2.6 Time to Irreversible Damage 
It is generally accepted that irreversible changes begin around 6 to 8 
hours following the onset of ACS, although determining the time of onset of ACS 
symptoms in itself is often quite challenging (Elliott & Johnstone 2003; Gourgiotis 
et al. 2007; Guo et al. 2019; Mabvuure et al. 2012; von Keudell et al. 2015). 
However, reports indicate that irreversible damage can also be seen much 
earlier, e.g. within 3 hours of ACS onset (Vaillancourt et al. 2004). A study by 
Sheridan and Matsen (1976) found that early fasciotomies (within 12 hours of 
onset of ACS) resulted in 68% of extremities with normal function and 4.5% 
complication rate, while late fasciotomy (mean 37.1 hours from ACS onset) 
produced only 8 percent of extremities with normal function and a 54% 
complication rate (Sheridan & Matsen 1976). Another study reported on patients 
who were operated within three hours of injury already showing evidence of 
muscle necrosis and complete muscle necrosis in the affected compartment 




of ACS, Labbe et al. (1987) demonstrated upwards of 90% leg muscle necrosis 
within 5 hours of ischemia (Labbe et al. 1987). 
 
1.2.7 Surgeon Variability 
It has been demonstrated that there is a degree of variability among 
surgeons in the diagnosis and treatment of ACS (O’Toole et al. 2009). A 
comparison of seven surgeons within the same institution found a wide variation 
of ACS diagnosis, ranging from 2% to 24% of the tibial fractures assessed. The 
use of compartment pressure monitors also greatly varied (1.7% to 28.6%), with 
similar variation to the percentage of ACS diagnosis (O’Toole et al. 2009). 
 
1.2.8 Medical-Legal Implications 
ACS is often subject to litigation. A review found that the factors leading to 
unsuccessful defences included poor documentation, poor physician 
communication, lack of action once neurovascular signs and symptoms were 
identified, increased number of concerning clinical findings, and increased time to 
surgery (Bhattacharyya & Vrahas 2004). Furthermore, given the magnitude and 
urgency in the treatment of ACS, information disclosed to obtain informed 
consent for surgery was often found to be incomplete. Risk of infection, risk of re-
operation, the potential need for staged-operations, skin grafts, negative 
pressure vacuum dressing, renal failure, and long-term complications were often 





1.3 MANAGEMENT OF ACS 
 ACS constitutes a surgical emergency. When ACS is suspected, all 
external compressive forces, such as casts or occlusive dressings, should be 
removed immediately. The affected limb should be elevated to the level of the 
heart (but not higher) to maximize perfusion (Forsh & Wolinsky 2013; Matsen et 
al. 1980). If the signs and symptoms of ACS persist, surgical fasciotomy of all 
compartments remains the gold standard. Although numerous nonoperative 
treatments of ACS have been studied in various models (tissue ultrafiltration, 
hyperbaric oxygen therapy, non-steroidal anti-inflammatory drugs (NSAIDs), 
mannitol, antioxidants), there is no conclusive evidence to support their use as a 
first-line treatment (Donaldson et al. 2014; Harvey et al. 2012; McLaughlin et al. 
2014; McMillan et al. 2019). 
 
1.3.1 Limb Anatomy 
1.3.1.1 Leg  
The lower leg is the most commonly affected limb in ACS. It includes two 
bones (tibia and fibula) and is divided into four compartments: anterior, lateral, 
deep posterior, and superficial posterior (Thompson 2016) (Figure 1.1).  
The anterior compartment includes the tibialis anterior, extensor hallucis 
longus, extensor digitorum longus, and peroneus tertius muscles. These muscles 
function primarily in foot and ankle dorsiflexion, are innervated by the deep 
peroneal nerve, and the blood supply mainly comes from the anterior tibial artery. 



















Figure 1.1 Compartments of the leg. Cross-sectional view of the leg 
including the tibia and fibula as well as muscles separated into four 
osseofascial compartments: anterior, lateral, deep posterior, and 
superficial posterior. 




and fibula posteriorly, and the anterior intermuscular septum laterally (Thompson 
2016). 
The lateral compartment includes the peroneus long and brevis muscles. 
They are innervated by the superficial peroneal nerve and are supplied by the 
anterior tibial and fibular arteries. The muscles function as the primary foot 
evertor while having secondary functions in ankle plantarflexion. The fibula 
borders the compartment medially while the anterior and posterior intermuscular 
septum borders the front and back, respectively (Thompson 2016). 
The muscles in the posterior compartments are mainly responsible for the 
plantarflexion of the foot and ankle. While the tibial and fibular arteries, as well as 
the tibial nerve, reside in the deep posterior compartment, they are responsible 
for vascularizing and innervating both posterior compartments. The deep 
posterior compartment includes the flexor hallucis longus, flexor digitorum 
longus, tibialis posterior, and popliteus muscles while the superficial posterior 
compartment is comprised of the gastrocnemius, soleus, and plantaris muscles. 
The compartments are separated by the transverse intermuscular septum 
(Thompson 2016). 
 
1.3.1.2 Forearm  
 The forearm is the second most commonly affected limb in ACS. The 
forearm, along with the radius and ulna bones, contains three compartments: the 




posterior forearm, and the mobile wad (brachioradialis, extensor carpi radialis 
longus and brevis) (Thompson 2016) (Figure 1.2). 
The anterior forearm muscles are primarily responsible for hand and wrist 
flexion, as well as forearm pronation. These muscles are either innervated by the 
median nerve or by the anterior interosseous nerve, a branch of the median 
nerve. They are vascularized by both the ulna and radial arteries (Thompson 
2016). 
The posterior (or dorsal) forearm muscles are primarily responsible for 
hand and wrist extension as well as forearm supination. These muscles are 
innervated by the posterior interosseous nerve, a branch of the radial nerve. 
They are vascularized by branches of the radial and ulnar arteries (Thompson 
2016).  
 The mobile wad muscles act as secondary elbow flexors proximally. While 
the brachioradialis also assists radioulnar joint supination and pronation during 
elbow flexion, the extensor carpi radialis longus and brevis allow wrist extension 
and hand abduction. The mobile wad is innervated by the radial nerve 
(brachioradialis and extensor carpi radialis longus) as well as the posterior 
interosseous nerve (extensor carpi radialis brevis). They are vascularized by the 
radial artery and brachii profunda (Thompson 2016). 
 
1.3.2 Fasciotomy 
The concept of fasciotomy surfaced early in the 1900s. As physicians 



















Figure 1.2 Compartments of the forearm. Cross-sectional view of the 
forearm including the radius and ulna as well as muscles separated 
into three different osseofascial compartments: dorsal, volar and 
mobile wad. 





reports of myotomies and nerve release were published (Thomas 1909). In 1911, 
Bardenheuer described a fasciotomy-type technique, termed aponeurectomy, as 
an operative treatment for patients with impending Volkmann’s contracture 
(Bardenheuer 1911). The procedure was then advocated by Murphy (1914), who 
argued that ischemic paralysis was caused by venous obstruction, hence splitting 
the deep fascia would relieve the pressure (Murphy 1914). Jepson (1926) also 
reported that decompression helped prevent ischemic contractures (Jepson 
1926). 
Fasciotomy has since become the forefront of treatment for ACS 
(Sheridan & Matsen 1976). By releasing the skin and fascia, the fasciotomy 
procedure decompresses the affected compartment(s), allowing the soft tissues 
to expand and increase in volume, immediately reducing the compartment 
pressures (Schmidt 2017). 
 
1.3.2.1 Threshold for Fasciotomy 
 Controversy and variability exist when making decisions to intervene. 
While some authors advocate for continuous pressure monitoring or routine 
compartment pressure checks on all patients at risk, it is generally accepted that, 
in the absence of risk factors, the diagnosis of ACS and the decision to intervene 
surgically can be made based on clinical symptoms alone. However, if there are 
any equivocal symptoms or ambivalence, compartment pressure measurements 




 The thresholds for compartment pressure measurements are also 
controversial. The evidence is shifting towards the use of Δp (McQueen & Court-
Brown 1996); however, false positive rates may be more significant than 
previously believed. A study of patients with tibial shaft fractures but no clinical 
evidence of ACS and who did not undergo fasciotomy reported that if the 
threshold for surgery of Δp <30mmHg and <20mmHg had been applied, 35% 
and 24% of patients, respectively, would have met the criteria for fasciotomy 
based on compartment pressures alone (Whitney et al. 2014).  
 
1.3.2.2 Techniques for Fasciotomy 
The leg fasciotomy can be done either through a 1-incision technique 
laterally or two incisions medially and laterally (Forsh & Wolinsky 2013; von 
Keudell et al. 2015) (Appendix I). In the forearm fasciotomy, the volar incision is 
performed using either a radial or ulnar curvilinear incision. If needed, a dorsal 
incision extending from the lateral epicondyle to the centre of the wrist at the 
level of the radioulnar joint is made for the posterior forearm (Forsh & Wolinsky 
2013; Gourgiotis et al. 2007) (Appendix I). 
 
1.3.2.3 Delayed Fasciotomy 
Some authors argue that fasciotomy should be considered even during 
late presentation due to the potential of salvaging any remaining muscle function 
(Olson & Glasgow 2005), as well as decreasing the risk of systemic 




No guidelines exist, particularly for patients with clearly missed ACS, no viable 
muscle function following the onset of symptoms for more than 24 to 48 hours, 
and no nerve injury or nerve block to alter the examination. In this scenario, 
supportive care has been the main indication, including adequate fluid 
resuscitation, analgesics, and splinting, unless there is evolving limb necrosis or 
systemic involvement requiring source control (Mabvuure et al. 2012; Schmidt 
2017; von Keudell et al. 2015). 
Finkelstein et al. (1996) reported that delayed fasciotomy (patients 
underwent fasciotomies at an average 56 hours after lower limb ACS was 
established) can result in death due to multi-organ failure or amputation due to 
infection and sepsis (Finkelstein et al. 1996). Another study reported an infection 
rate of 28% in patients undergoing late fasciotomy (>12 hours) (Williams et al. 
1997). Complication rates of 4.5% were reported for an early fasciotomy (less 
than 12 hours after onset of ACS, with a mean 5.3 hours) and 54% for late 
fasciotomy (more than 12 hours after onset of ACS, with a mean 37.1 hours). 
Additionally, only 8% of patients in the late group regained normal function 
(Sheridan & Matsen 1976). 
 
1.3.2.4 Complications of Fasciotomy 
Complication rates of fasciotomy are significant. In a study by Fitzgerald et 
al. (2000), long-term complications of fasciotomy included altered sensation 
around the wound margins (77%), persistent wound pain (10%), dry scaly skin 




tethered scar (26%), recurrent ulceration (13%), muscle herniation (13%), and 
tethered tendon (7%). Furthermore, 12% and 28% of patients stated that they 
changed occupation and hobbies, respectively, following fasciotomy (Fitzgerald 
et al. 2000). Other complications of fasciotomy include delayed wound closure, 
need for surgical reconstruction with grafts or flaps, chronic pain, nerve injury, 
infection, permanent muscle weakness, chronic venous insufficiency, renal 
failure, and death (Schmidt 2017). 
 
1.3.3 Alternative Treatments 
To-date, open fasciotomy remains the gold standard in the treatment of 
ACS.  Given the morbidity and potential complications, non-surgical management 
is rather used as an adjunct to fasciotomies or when fasciotomies are absolutely 
contraindicated (Donaldson et al. 2014; McMillan et al. 2019). Several different 
techniques have been tested in various models of ACS: tissue ultrafiltration, 
hyperbaric oxygen, mannitol, anti-inflammatory medications, and antioxidants. 
 
1.3.3.1 Tissue Ultrafiltration 
Odland and colleagues explored the use of tissue ultrafiltration (TUF) as a 
potential therapy for ACS. The technique consists of an insertion of small hollow 
fibers via catheters into muscle compartments to remove interstitial fluid and thus 
decrease compartmental pressures (Harvey et al. 2012). The technique was first 
tested in a porcine model of hindlimb ACS by Odland et al. (2005), demonstrating 




limb (Odland et al. 2005). A small, randomized pilot study was then undertaken in 
10 patients with tibial fracture. Although no patients suffered from ACS during the 
study period, one patient developed ACS in the lateral compartment of the lower 
leg and underwent a 4-compartment fasciotomy 22 hours after the TUF catheter 
was removed and 46 hours after fracture fixation (Odland & Schmidt 2011). 
 
1.3.3.2 Hyperbaric Oxygen Therapy 
Hyperbaric oxygen therapy allows the delivery of 100% oxygen to the 
patient (normal atmospheric air contains 21% oxygen). In a case report of a 43-
year-old male bitten by a Western diamondback rattlesnake who developed ACS 
and was recommended fasciotomy by the consulting orthopaedic surgeon, due to 
the patient’s refusal of fasciotomy, the therapy consisted of antivenom, mannitol, 
and hyperbaric oxygen; the patient fully recovered from the envenomation 
without any long-term complications (Gold et al. 2003). 
  Given the high cost of equipment and paucity of evidence, hyperbaric 
oxygen therapy has been largely abandoned as a treatment of ACS (Greensmith 
2004), although limited evidence shows that it does offer some value as an 
adjunct to standard ACS therapy. 
 
1.3.3.3 Mannitol 
Mannitol, a type of sugar alcohol, has previously been suggested to offer 
protective effects as an osmotic agent, thereby decreasing muscle edema 




mannitol was reported in some case reports: a patient presenting with a heat 
stroke who later developed ACS of the anterior compartment of the right lower 
leg was treated with mannitol alone and developed only mild residual weakness 
in the right lower extremity (Daniels et al. 1998); a snakebite that progressed into 
ACS was treated with mannitol as an adjunct (along with hyperbaric oxygen and 




Significant leukocyte activation (i.e. inflammation) is one of the driving 
forces of ACS pathophysiology (Lawendy et al. 2015). As such, the potential of 
non-steroidal anti-inflammatory medications as a therapy for ACS has also been 
explored in animal models. Cyclooxygenase (COX) enzymes play a key role in 
prostaglandin formation, mediating inflammatory processes. While COX-1 is 
expressed constitutively, COX-2 enzymes are upregulated during pro-
inflammatory state (Tsatsanis et al. 2006). In a rat model of ACS, Manjoo et al. 
(2010) demonstrated improved muscle perfusion and decreased tissue damage 
in animals treated with indomethacin, a COX-2 inhibitor. The observed effects 
were a result of indomethacin’s inhibitory effects on activated neutrophils and its 
effects as a free radical scavenger. However, it did not affect the apoptotic 







Antioxidants have potential benefits in situations of oxidative stress-
induced microvascular injuries such as trauma, ischemia-reperfusion, sepsis, and 
organ failure (Oudemans-van Straaten et al. 2014; Spoelstra-de Man et al. 
2018). A previous study of limb ACS demonstrated that exogenous 
administration of superoxide dismutase (SOD) antioxidant (an intrinsic enzyme) 
and hydroxyl radical inhibitors decreased compartment pressure rise and 
improved muscle perfusion (Perler et al. 1990). Meanwhile, the administration of 
SOD and mannitol, a hydroxyl radical scavenger, in a canine model of ACS 
significantly reduced muscle necrosis compared to control groups but did not 
prevent compartment pressure rise (Ricci et al. 1990).  
Vitamin C (ascorbic acid) has many antioxidant and immune-supporting 
effects such as helping the mediation of direct free radical scavengers, reducing 
reactive oxygen species (ROS) production, and increasing the immune response 
(Spoelstra-de Man et al. 2018). It has been shown that in a rat model of ACS 
within the cremaster muscle, vitamin C pre-treatment in conjunction with 
decompression (fasciotomy equivalent) helped maintain muscle function and 
decreased extracellular neutrophil infiltration and soft tissue edema (Kearns et al. 
2004). 
N-acetyl cysteine (NAC), a precursor of glutathione, is a potent antioxidant 
by acting as a free radical scavenger (Lejay et al. 2018). Kearns et al. (2010) 




improved muscle viability following decompression and NAC treatment in a 
rodent cremasteric striated muscle model of ACS (Kearns et al. 2010). 
 
1.4 PATHOPHYSIOLOGY OF ACS 
1.4.1 Historical Perspective 
The first description of ACS originates in 1881 by Volkmann. Following his 
observation on outcomes of bandages being applied too tightly, he suggested 
that ischemic contractures and limb paralysis secondary to ACS following 
traumatic injuries were a result of arterial obstruction rather than neurologic 
injuries (Volkmann 2007; von Volkmann 1881). Greater attention was brought in 
1884 following Leser’s report of seven upper extremity cases treated with plaster 
cast and consequent contractures (Leser 1884; Thomas 1909). However, much 
debate remained regarding the pathophysiology of ACS.  Over the next century, 
multiple theories have been postulated, including arterial injuries and arterial 
spasms (Griffiths 1940; Plewes 1940), venous obstruction (Bardenheuer 1906; 
Brooks 1922; Jepson 1926; Murphy 1914; Plewes 1940), nerve injuries 
(Hildebrandt 1906; Thomas 1909), and thromboembolism (Lander 1895; Thomas 
1909). 
In the 1930s and 1940s, the correlation between increased tissue 
pressures and ischemia started surfacing (Hughes 1948; Lewis 1936). Although 
fasciotomy or fasciotomy-type procedures had been previously described, the 
concept of fascial splitting or decompression became more widely accepted and 




Reneman 1975). In 1975, Matsen unified the concepts from the scientific 
evidence gathered over the years. He emphasized that the underlying 
pathophysiology of ACS was the same, regardless of aetiology, and could occur 
within any closed space, regardless of location. Moreover, immediate surgical 
decompression of the affected compartments is crucial while suggesting that the 
pressure required to cause irreversible damage was not an absolute value but 
rather dependent on local factors such as time under elevated ICP, vascular 
tone, local blood perfusion, and metabolic rates (Matsen 1975).  
While many theories have been postulated, the underlying mechanism 
leading to tissue ischemia, myonecrosis, and loss of limb function during 
sustained ICP elevation is not yet fully understood. However, it is widely 
accepted that increased compartment pressures due to inelastic fascia following 
a bony or soft tissue insult leads to progressive microvascular dysfunction and 
tissue hypoperfusion. This leads to impaired gas exchange and inability to meet 
tissue metabolic demands (Schmidt 2017; von Keudell et al. 2015). Furthermore, 
elevated ICP-generated ischemia is associated with leukocyte recruitment, as 
well as local and systemic pro-inflammatory cascades, ultimately leading to 
cellular anoxia and death, tissue necrosis, and potential loss of limb function 
(Donohoe et al. 2018; Lawendy et al. 2015). It is also important to note that 
unlike complete ischemia, the deleterious effects of ACS occur despite a patent 
macrocirculation where distal pulses are usually palpable unless there is 




result of ACS rather than the cause of tissue necrosis (Gourgiotis et al. 2007; 
Hoekman et al. 2005; Leach et al. 1967; Seddon 1966; Whitesides et al. 1975).  
 
1.4.2 Microcirculation in ACS 
1.4.2.1 Normal Microcirculation 
In normal skeletal muscle, arterioles, capillaries, and venules form the 
microcirculatory system (Figure 1.3). Gas exchange and nutrient delivery occur in 
the capillaries of terminal vascular beds. In the terminal vascular beds, arterioles 
divide into multiple closely spaced capillaries situated along parenchymal cells to 
allow oxygen and nutrient exchange. Following material exchange, the blood 
flows through the venules and into the systemic venous circulation. In the 
microcirculatory system, all vessels are comprised of a single layer of vascular 
endothelial cell lining sitting on a layer of extracellular matrix (basement 
membrane). The arterioles are surrounded by smooth muscle mesenchymal cells 
to allow contractility, while capillaries and post-capillary venules are surrounded 
by pericytes rather than smooth muscle cells. The post-capillary venules also 
have a rather larger cross-sectional area compared to the corresponding 
arterioles resulting in decreased luminal pressures. This allows perfusion through 
an arteriovenous pressure gradient (Brown et al. 2006). 
 
1.4.2.2 Microcirculatory Dysfunction 
The exact mechanism by which microcirculatory dysfunction and tissue 




















Figure 1.3 Microcirculation of the skeletal muscle. Normal microcirculation 
where an arteriole branches into capillaries. Oxygenated blood 
flows from the arterioles (red) into the capillary beds and 
deoxygenated blood flows from the capillary beds to collect into the 
post-capillary venules (blue).  





postulated in an attempt to explain the phenomenon in relation to increased 
compartment pressures, including the critical closing pressure theory, 
microvascular occlusion theory, and arteriovenous (AV) gradient theory. The 
critical closing pressure theory suggests that the intravascular arteriolar mural 
tension must be sufficiently elevated to overcome extravascular tissue pressure. 
Disruption of this equilibrium and an extravascular ICP above the arteriolar mural 
pressure in compartment syndrome leads to abrupt arteriole occlusion resulting 
in ischemia (Burton 1951; Singh et al. 2004). Additionally, Ashton (1975) also 
postulated other mechanisms, including active arteriolar closure mediated by 
vasomotor tone due to a decrease in intravascular pressure or extravascular 
pressure increase (Ashton 1975). However, the theory has been questioned 
when a rabbit model of ACS revealed increased venous pressures and total 
intramuscular pressures, while arteriolar dilatation occurred (Reneman et al. 
1980). Additionally, in a rodent model, Vollmar et al. (1999) demonstrated no 
signs of arteriolar collapse or spasm with elevated intracompartmental pressures 
despite blood flow cessation and decreased venular diameter (Vollmar et al. 
1999).  
In the microvascular occlusion theory, it is assumed that increased ICP 
leads to capillary collapse as tissue pressures overcome intracapillary pressures. 
Given the low baseline capillary pressures, small extravascular pressure 
increments can lead to a reduction in blood flow and subsequent ischemia 




demonstrated, in a rat model, that capillaries did not collapse despite an increase 
in ICP and even complete cessation of capillary perfusion (Hartsock et al. 1998).  
The assumption behind the AV gradient theory is that with rising 
intracompartmental pressures, the intraluminal venous pressures also increase, 
causing a decrease in the AV gradient and subsequent decrease in perfusion. 
This leads to a rise in interstitial pressure due to the extrusion of fluids into the 
interstitial space. While the continuous arterial perfusion contributes to increasing 
edema and swelling, the increasing extravascular pressures eventually decrease 
arterial perfusion, and the cellular metabolic demands are no longer met (Elliott & 
Johnstone 2003; Mabvuure et al. 2012; McLaughlin et al. 2014; McMillan et al. 
2019). In animal models of ACS, it has been shown that increasing ICP and 
extravascular pressure resulted in the reduction of venule diameter, thus 
decreasing local perfusion and effectively decreasing the AV gradient, without 
complete closure of vessels (Hartsock et al. 1998; Reneman et al. 1980; Slaaf et 
al. 1987; Vollmar et al. 1999). The AV gradient theory is the most widely 
accepted theory explaining the relationship between the microcirculation and 
increased ICP. However, it only accounts for passive microvasculature changes 
in response to pressure changes and does not consider local adaptive 
responses, endothelial structural changes, and the inflammatory responses 







1.4.3 Ischemia and Reperfusion 
The exact underlying pathophysiology of ACS still needs to be fully 
elucidated. However, the consequences of untreated ACS appear to share 
characteristics with ischemia-reperfusion (I-R) injuries. In general, morbidity and 
cellular death from ischemic events alone are either a result of prolonged 
ischemia (vasculopathy) or lack of oxygen supply due to interrupted blood flow 
for periods beyond the organs’ hypoxic threshold (Grace 1994). In ischemic 
events, depletion of intracellular adenosine triphosphate (ATP) leads to cellular 
membrane damage and loss of transmembrane electrical potential. This leads to 
acidosis, osmotic shock, and intracellular calcium overload, with eventual 
irreversible mitochondrial damage, protein and enzymatic leakage, and cellular 
apoptosis (Grace 1994; Hamburg & Creager 2017; Sharfuddin & Molitoris 2011). 
However, histologic findings are often ‘normal’ with preserved tissue architecture 
and acellularity, while I-R injuries are characterized by tissue necrosis and 
neutrophil infiltration, also observed in ACS (Epstein & McCord 1985; Francis & 
Baynosa 2017; Lawendy et al. 2011, 2014). Therefore, understanding the 
inflammatory process of I-R injury may help elucidate the mechanisms that lead 
to myonecrosis and systemic complications in ACS. 
 
1.4.3.1 Complete Versus Partial Ischemia  
ACS is believed to be a type of I-R injury (Francis & Baynosa 2017; 
Gourgiotis et al. 2007; Lawendy et al. 2015). However, the degree of ischemia in 




the effects of 3 hours of partial ischemia and complete ischemia, followed by 
reperfusion in canine animal models. Although both the complete and partial 
ischemia induced cell membrane dysfunction, partial ischemia led to greater 
damage than complete ischemia (Perry 1988; Perry et al. 1984; Roberts et al. 
1985). Heppenstall and colleagues (1986) demonstrated that increased ICP 
resulted in decreased levels of ATP, more severe muscle acidosis and cellular 
degeneration compared to tourniquet-induced I-R (Heppenstall et al. 1986). 
Conversely, Conrad et al. (2005) found that partial ischemia resulted in 
significantly greater early inflammatory cytokine production than incomplete 
ischemia. However, after 24 hours of reperfusion, less tissue viability was found 
following complete ischemia (Conrad et al. 2005). 
 
1.4.3.2 Low-Flow Ischemia 
Recent animal model studies have demonstrated ACS as a “low-flow” 
ischemic state (Lawendy et al. 2011, 2015) (Figure 1.4). Normal microvascular 
perfusion is predominantly of continuous type (Lawendy et al. 2011; Sadasivan et 
al. 1997). However, as the ICP increases, capillaries progress to intermittency 
and non-perfusion, although some capillaries remain continuously perfused, thus 
decreasing gas exchange and nutrient delivery overall. This partial ischemic state 
results in a significant degree of leukocyte activation, cytokine production, and 
tissue necrosis (Donohoe et al. 2018; Lawendy et al. 2011, 2015). Therefore, 
while the underlying pathophysiology of ACS may not be due to pure I-R 




















Figure 1.4 Microcirculatory dysfunction in compartment syndrome. Hypo-
perfusion of the capillary beds (low-flow ischemia) causes tissue 
injury (brown cells). Subsequently, leukocyte activation occurs in 
post-capillary venules and results in inflammation. LKC: leukocytes.  





microvascular dysfunction, tissue ischemia, and eventual macrocirculation 
deficits. 
 
1.4.4 Reperfusion Injury 
Logically, reperfusion of ischemic tissues serves to restore blood flow, 
tissue oxygenation, nutrient delivery, and removal of toxic metabolites. 
Paradoxically, it further exacerbates tissue injury and cell death.  
The concept of reperfusion injury surfaced in the early 1940s following air 
raids during World War II. Patients with crush injuries had localized symptoms 
but were systemically well. However, upon restoration of blood flow, they were 
found in shock within hours and many passed away within one week (Bywaters & 
Beall 1941; Bywaters et al. 1941). Reperfusion following ischemia results in 
multiple systemic disturbances, including metabolic acidosis, hyperkalaemia, 
myoglobinemia, myoglobinuria, and ultimately renal failure (Erdos et al. 2011). 
The systemic return of acidotic blood with venous blood pH usually below 7.2 
causes metabolic acidosis, while intracellular potassium (cation) leakage leads to 
hyperkalaemia and could be severe enough to cause death. Additionally, 
intracellular enzymes, such as creatinine phosphokinase, lactic acid 
dehydrogenase, and glutamic-oxaloacetic transaminase, can lead to 
rhabdomyolysis (Grace 1994). Furthermore, ischemic muscles release myoglobin 
that can lead to acute renal failure (Matsen 1975; von Keudell et al. 2015). 
Re-introduction of oxygen molecules leads to the formation of ROS, 




infiltration, inflammatory cascades, and changes in microvascular permeability 
(Francis & Baynosa 2017). Several studies have shown that reperfusion of 
ischemic tissues with anoxic (without oxygen) blood or limited oxygenated blood 
produced considerably less tissue injury (Gute et al. 1998). Consequently, 
ischemic tissue injuries appear to be exacerbated by the formation of ROS 
(Grace 1994; Gute et al. 1998; Wright et al. 1988). 
 
1.4.4.1 Reactive Oxygen Species and Free Radicals 
ROS are oxygen-containing reactive molecules that display much greater 
reactivity with other molecules than molecular oxygen (O2) does. Free radicals 
are a type of ROS as they contain one or multiple unpaired electrons (Toyokuni 
1999). ROS normally play an important role in regulating cell signalling, growth, 
and apoptosis. They are also vital in regulating immune, thyroid, and cognitive 
functions (Brieger et al. 2012). However, when ROS levels are supraphysiologic 
and overwhelm the antioxidant system, they become detrimental, leading to I-R 
injuries and various diseases, such as oncologic, cardiovascular, neurologic, and 
psychiatric disorders (Brieger et al. 2012; Francis & Baynosa 2017; Lushchak 
2015; Toyokuni 1999). 
Multiple sources of ROS have been described in biological systems, such 
as xanthine oxidase (XO) metabolism, by-products of leukocyte activation, 
mitochondrial electron transport chain, arachidonic acid metabolism, 
catecholamine autoxidation, endothelial cells, and prostaglandins (Cowled & 




leukocyte activation are the main drivers of ROS production in I-R. Superoxide 
anion and hydrogen peroxide appear to be the most commonly produced ROS, 
while others include, but are not limited to, hydroxyl radical, nitric oxide, and 
peroxyl radical (Brieger et al. 2012; Cowled & Fitridge 2011; Grace 1994; 
Toyokuni 1999). 
XO is a primary producer of ROS in I-R injuries: during the ischemic 
phase, glycogen breakdown in the mitochondria leads to increased lactic acid, 
resulting in a tissue pH drop, subsequently inhibiting ATP production and 
decreasing the transmembrane gradient. ATP is subsequently broken down into 
adenosis, inosine, hypoxanthine, and xanthine. Concomitantly, as the 
transmembrane gradient diminishes, intracellular sodium rises while potassium 
escapes into the extracellular space, and calcium is released from the 
mitochondria into the cytoplasm (Cowled & Fitridge 2011). Calpain, a calcium-
dependent cytosolic protease, is then activated, converting xanthine 
dehydrogenase (XD) to XO. During reperfusion, molecular oxygen reacts with 
XO, catalysing the formation of uric acid and superoxide anion. Superoxide anion 
can further be converted to hydrogen peroxide and hydroxyl radicals (Cowled & 
Fitridge 2011; Epstein & McCord 1985; Perry & Fantini 1987) (Figure 1.5). In 
contrast, in its physiologic role, XD reacts with nicotinamide adenine dinucleotide 
(NAD+), converting hypoxanthine to xanthine and NAD+ to nicotinamide adenine 
dinucleotide phosphate (NADPH) rather than reacting with molecular oxygen, 





















Figure 1.5 Generation of reactive oxygen species in ischemia-
reperfusion. During ischemia, ATP is degraded and XD converted 
to XO. Upon reperfusion, XO catalyses the conversion of 
hypoxathine to superoxide anions; these then initiate the production 
of hydrogen peroxide and superoxide radical, leading to lipid 
peroxidation and tissue damage.  




The evidence that free radicals play a major role in I-R has been shown in 
multiple experiments. Superoxide dismutase (SOD), a free radical scavenger, 
has been shown to decrease free radical levels and tissue damage (Gute et al. 
1998; Perler et al. 1990; Perry & Fantini 1987; Salvemini & Cuzzocrea 2003). 
Other endogenous antioxidants, such as catalase, glutathione peroxidase, 
histidine, and vitamin E play a significant role in maintaining equilibrium and 
physiologic levels of ROS; however, during I-R, the antioxidant system becomes 
overwhelmed and is unable to maintain its scavenging function (Francis & 
Baynosa 2017). 
 
1.4.4.2 Lipid Peroxidation 
A major consequence of ROS production is structural and functional 
damage to the phospholipid-derived cell membrane (Gaschler & Stockwell 2017; 
Grace 1994). Following reperfusion, superoxide contributes to free ferrous ion 
release, catalysing the formation of hydroxyl radicals and peroxyl radicals from 
hydrogen peroxide. These radicals then remove a hydrogen atom in the 
methylene group (-CH2-) between two unsaturated bonds (double covalent 
bonds) in the lipid molecule, which creates a new carbon-centred radical. When 
this new carbon-centred radical reacts with molecular oxygen, a lipid-peroxyl 
radical (ROO-) is formed; it then abstracts another hydrogen atom from another 
methylene group in the cell membrane, forming lipid peroxide (ROOH). Molecular 
oxygen then reacts with the newly created carbon-centred radical, creating a 
chain reaction, ultimately leading to cellular permeability and cell death (Cowled 





Plasma thromboxane A2 is derived from arachidonic acid that is released 
from lipid peroxidation. Released within minutes of I-R injuries, it promotes 
vasoconstriction and platelet aggregation (Mazolewski et al. 1999). A rat model 
of I-R with administration of thromboxane A2 receptor antagonist demonstrated a 
significant decrease in vasoconstriction (Mazolewski et al. 1999). 
 
1.4.4.4 Leukocyte Activation 
The production of ROS has a downstream effect on leukocyte activation 
and endothelial injury. Superoxide promotes the production of inflammatory 
mediators such as platelet-activating factor and leukotrienes. It also activates 
leukocyte chemoattraction and endothelial adhesion proteins, leading to 
neutrophil infiltration (Kubes et al. 1990a; Lehr et al. 1991; Lewis et al. 1988; 
Rubanyi & Vanhoutte 1986). Leukocyte chemoattraction creates an additive 
effect of ROS production through NADPH oxidase (Gute et al. 1998). 
Leukocytes contain NADPH oxidase and can oxidize O2 into superoxide; 
superoxide is further converted to hydrogen peroxide (Cowled & Fitridge 2011; 
Gute et al. 1998). Activated neutrophils undergo degranulation and release 
myeloperoxidase (MPO), which then catalyses the formation of hypochlorous 
acid (HOCl) from hydrogen peroxide and chloride ions. This ROS activates the 
secretion of matrix metalloproteinases (MMPs). MMP secretion is tightly 
controlled and plays an essential role in angiogenesis, arteriogenesis, and 




However, during I-R, MMP upregulation leads to further basement membrane 
and tissue destruction (Cowled & Fitridge 2011; Dejonckheere et al. 2011; Gute 
et al. 1998; Hobeika et al. 2008). 
Leukocyte proteinases, such as neutrophil elastase and MMPs, further 
amplify leukocyte adherence and endothelial transmigration (Owen 2008; Stowe 
et al. 2009). Previous mice studies with either neutrophil elastase or MMP-9 
deficiency demonstrated diminished leukocyte adherence, decreased brain 
infarct size and blood brain barrier deficiency, and reduced extracellular matrix 
destruction in cerebral I-R (Gidday et al. 2005; Stowe et al. 2009). Other animal 
studies showed significant decrease in liver injury (Okajima et al. 2004; Soejima 
et al. 1999), renal injury (Matsuyama et al. 2008), and pulmonary injury (Ishikawa 
et al. 2003) following neutrophil elastase inhibition in the context I-R. MMP 
inhibition also showed similar effects in animal studies of cardiac (Cheung et al. 
2000; Wang et al. 2002), cerebral (Chen et al. 2018), and renal as well as other 
tissue models (Kunugi et al. 2011) of I-R. Neutrophil elastases have been shown 
to independently promote neutrophilic and endothelial receptors that allow 
leukocyte adherence and transmigration (Woodman et al. 1993; Yamaguchi et al. 
1998) while MMPs have degrading effects on the basement membrane, 
extracellular matrix, and interstitial tissue (Cheung et al. 2000; Wang et al. 2002, 
Kunugi et al. 2011). 
Platelet-activating factors also play detrimental roles in causing interstitial 
edema and leukocyte adhesion to the endothelium. Free radicals promote the 




activating factors, a leukocyte chemoattractant. Lewis (1988) demonstrated that 
hydrogen peroxide catalysed the synthesis of platelet-activating factors via the 
endothelium, inducing leukocyte-endothelial adhesion (Lewis et al. 1988). 
Platelet-activating factor antagonists have also been found to play a role in 
attenuating leukocyte adhesion and cellular extravasation (Kubes et al. 1990a,b). 
Lipid peroxidation of the cell membrane leads to the release of arachidonic 
acid. Arachidonic acid then leads to the production of leukotrienes (LTs) 
(Gaschler & Stockwell 2017). LTs affect the endothelial cytoskeleton by 
increasing membrane permeability, smooth muscle contraction, and 
vasoconstriction (Cowled & Fitridge 2011), as well as activation of endothelial 
adhesion molecules, such as CD18 (Grace 1994). Furthermore, leukotriene B4 
also mediates neutrophil-generated hydrogen peroxide and elastase (proteolytic) 
production (Welbourn et al. 1991). 
 
1.4.4.5 Interaction Between the Endothelium and Leukocytes 
During reperfusion, neutrophils are recruited to the ischemic areas, adhere 
to the endothelium, and transmigrate into the extravascular space (Ley et al. 
2007). This is a multi-step process, initially described by Du Trochet in 1824 (Du 
Trochet 1824), known as the leukocyte adhesion cascade (Figure 1.6). While 
knowledge surrounding the leukocyte adhesion cascade is still evolving, the 
current model of the cascade features nine distinct steps: capture, rolling, slow-
rolling, arrest, adhesion, intravascular crawling, paracellular transmigration, and 










Figure 1.6 Leukocyte activation sequence in inflammation. Activated 
leukocyte sequence includes leukocyte capture/tethering, rolling, 
firm adhesion, arrest and extravasation. It is mediated by various 
adhesion molecules such as selectins, integrins, and Ig 
superfamily. 
Adapted with permission of Springer Nature from Ley, Laudanna et 








 The process of neutrophil capturing (known as endothelial tethering, 
where the neutrophil makes first endothelial contact) and rolling (slow movement 
along the endothelial lining) are mediated by selectins and integrins. Initially, L-
selectin is expressed on leukocytes; P-selectin and E-selectin are expressed on 
the endothelium (Ley et al. 2007). During reperfusion, P-selectin (normally stored 
in α-granules of platelets and Wiebel-Palade bodies of the endothelium) is 
quickly expressed on to the endothelial cell surface (Cowled & Fitridge 2011; 
Lum & Roebuck 2001). Inflammatory mediators promote de novo transcription 
and production of E-selectin, taking several hours until full expression (Ley et al. 
2007).  
Leukocyte rolling is then mediated by integrins, leading to eventual firm 
adhesion and arrest. Leukocyte cell surface receptors α4β7 integrin and very late 
antigen-4 (VLA-4) contribute to leukocyte rolling along the endothelium, 
interacting with mucosal vascular addressin cell-adhesion molecule-1 
(MADCAM-1) and vascular cell-adhesion molecule-1 (VCAM-1), respectively. 
(Cowled & Fitridge 2011; Ley et al. 2007). 
Leukocyte adhesion is mediated by integrins and immunoglobulin 
superfamily (Ig). The CD11/CD18 αβ-integrin complexes mediate adhesion: 
CD11a/CD18, also known as lymphocyte function-associated antigen-1 (LFA-1), 
is expressed on all leukocytes, while CD11b/CD18, also known as macrophage-
associated receptor-1 (MAC-1), is expressed on certain monocytes, 
macrophages, lymphocytes, natural killer cells, neutrophils, and granulocytes 




expressed. Both neutrophilic-integrin complexes interact with immunoglobulin 
superfamily, including intercellular adhesion molecules 1 and 2 (ICAM-1 and 
ICAM-2) on the endothelium, whereas VLA-4 binds with VCAM-1 during the 
rolling phase to initiate arrest. ROS, along with pro-inflammatory cytokines, 
further promote CD11/CD18 complex and ICAM-1 interaction (Cowled & Fitridge 
2011; Eltzschig & Collard 2004; Ley et al. 2007; Lum & Roebuck 2001). 
Neutrophil transmigration is triggered by a chemoattractant 
transendothelial gradient. Emigrating leukocytes must pass through three distinct 
barriers: endothelial cell (rapid penetration, <5 minutes), endothelial cell 
basement membrane (penetration time around 5 to 15 minutes), and pericytes. 
During I-R, β-integrins promote greater leukocyte-endothelial interactions, 
leading to the transmigration of neutrophils. Platelet-associated cell adhesion 
molecule-1 (PECAM-1), also a member of the immunoglobulin superfamily, is 
constitutively expressed on endothelial cells, leukocytes, and platelets. It is a 
major protein facilitating transmigration of leukocytes through both the 
paracellular route (at the junctions between endothelial cells) and the 
transcellular route (within the body of the endothelium) (Albelda et al. 1991; Ley 
et al. 2007; Woodfin et al. 2007). The leukocyte-bound PECAM-1 interacts with 
endothelial PECAM-1 promoting transendothelial leukocyte movement, upstream 
integrin activation (including MAC-1), and upregulates neutrophil integrin α6β1, 
which enables PECAM-1-mediated migration through the perivascular basement 
membrane. (Berman & Muller 1995; Privratsky et al. 2010). Studies of pro-




reduced leukocyte endothelial transmigration, and reduced migration into the 
interstitium when PECAM-1 was inhibited (Privratsky et al. 2010; Ley et al. 2007; 
Woodfin et al. 2007). Other endothelial mediators of transmigration are junctional 
adhesion molecules (JAMs), including JAM-A, JAM-B, JAM-C, as well as ICAM-
1, ICAM-2, CD99 antigen, and endothelial cell-selective adhesion molecules (Ley 
et al. 2007; Lum & Roebuck 2001). Junctional adhesion molecules interact with 
leukocyte ligands LFA-1, VL-4, and MAC-1. (Lum & Roebuck 2001; Tuma et al. 
2008; Woodfin et al. 2007). 
 
1.4.4.6 Cytokines/Chemokines 
Cytokines and chemokines play a significant role in the pro-inflammatory 
response of I-R injury. During I-R, calcium phosphate complexes and uric acid 
levels increase and bind onto inflammasomes, assisting with the 
upregulation/production of tumour necrosis factor-α (TNF-α) and interleukin-1β 
(IL-1β) by tissue macrophages and neutrophils (Kalogeris et al. 2016; Martinon et 
al. 2002). These cytokines enable toll-like receptor stimulation through 
intracellular pathways, leading to an upregulation of nuclear factor kappa light-
chain of activated B cells (NF-κB) transcription factor activity. As a result, 
platelet-activating factors, monocyte chemoattractant protein-1 (MCP-1), 
chemokine ligand 5 (also known as RANTES), and other interleukins (IL-) 
including IL-6 and IL-8 are produced and released. Cytokines and chemokines 




neutrophil chemoattraction, cellular infiltration, and edema (Kalogeris et al. 2016; 
Lum & Roebuck 2001; Lutz et al. 2010; Martinon et al. 2002). 
Functions of TNF-α include chemoattraction of neutrophils, upregulating 
ICAM-1 expression on the vascular endothelium, stimulating production of 
downstream cytokines, and apoptosis. It has a high affinity for TNF-α receptor-1 
and TNF-α receptor-2 (Cowled & Fitridge 2011). Studies have demonstrated that 
inhibition of TNF-α receptor-1 can prevent downstream effects and programmed 
cell-death (Jiang et al. 2009).  Unlike complete ischemia followed by reperfusion 
(Bihari et al. 2017), ICP elevation in a rat model of ACS led to a sustained 
increase in serum TNF-α levels, with a second peak (biphasic TNF-α elevation) 
occurring after fasciotomy (Lawendy et al. 2016). Meanwhile, IL-1β is released by 
mast cells and macrophages to stimulate the production of downstream 
cytokines. IL-1β inhibition studies have shown to lessen the pro-inflammatory 
response, chemokine expression, and apoptotic events in I-R injuries (Furuichi et 
al. 2006; Lutz et al. 2010). 
In a rat model of ACS, neutralizing TNF-α alone or both TNF-α and IL-1β 
together significantly reduced tissue injury but not with IL-1β neutralization alone. 
TNF-α with or without IL-1β neutralization significantly decreased leukocyte 
activation and inflammation, while IL-1β neutralization alone had partial 







1.4.4.7 Nitric Oxide 
Nitric oxide (NO) is synthesized by nitric oxide synthase (NOS) enzyme 
existing in three forms: constitutive (cNOS), inducible (iNOS), and endothelial 
(eNOS). During the ischemic phase, there is a surge of eNOS within minutes. 
However, during reperfusion, eNOS functions decline and NO levels, important in 
maintaining vascular tone, decrease. During later stages of reperfusion, cytokine-
mediated upregulation of iNOS from mast cells, neutrophils, and macrophages 
leads to an increase in NO production. However, NO function is bimodal. While 
its production from eNOS during ischemia appears to be cytoprotective and acts 
as an antioxidant, the late surge from iNOS expression results in further oxidative 
stress and interacts with superoxide to form peroxynitrite free radical (Cowled & 
Fitridge 2011; Khanna et al. 2005). 
 
1.4.4.8 Complement 
I-R has also been shown to lead to an activation of the complement 
cascade. Active peptides, such as C3a and C5a, increase microvascular 
permeability and exert chemotactic effects on neutrophils. They also increase 
CD18 expression and increase neutrophil adhesion to the endothelium (Grace 
1994). Heideman et al. (1988) demonstrated increased serum C3a and C5a as 
well as elevated serum terminal complement complexes in patients with acute 
limb ischemia. Following amputation, these peptide levels returned to normal 
range. Multiple complement inhibitors, at various points of the complement 




(Heideman et al. 1988). However, none were able to completely prevent tissue 
injury, suggesting that complement activation plays only a partial role in the 
underlying pathophysiology of I-R (Arumugam et al. 2006).  
Despite their important physiologic functions in maintaining homeostasis, 
inflammation and ROS production in the context of ACS and I-R injuries 
contribute to extensive tissue damage, organ dysfunction, and systemic 
complications. 
 
1.5 HEME METABOLISM AND OXIDATIVE STRESS 
Despite the dependence of living organisms on oxygen to survive, the 
oxygen required to maintain life is intrinsically toxic due to its capabilities of 
inducing oxidative stress. Therefore, compensatory mechanisms have evolved to 
allow for survival in such toxic environment. One of the most ubiquitous 
mechanisms is heme oxygenase (HO) metabolism (Morse & Choi 2005). 
The importance of HO was highlighted by Yachie et al. (1999), who 
reported on the first case of HO deficiency: a 2-year-old child presented with 
growth retardation, developmental delay, hepatomegaly, asplenia, and persistent 
hemolytic anemia requiring regular erythrocyte transfusions. The mother had two 
previous intrauterine death that could have been related to HO deficiency; the 







1.5.1 Heme Oxygenase 
HO is an enzyme that catalyses heme degradation (Figure 1.7). It was first 
described in 1968 by Tenhunen and colleagues (Tenhunen et al. 1968). 
Subsequently, three isoforms of HO were isolated: the inducible form, HO-1, and 
constitutively expressed HO-2 and HO-3 (Hayashi et al. 2004; Maines et al. 
1986; Mccoubrey et al. 1997). 
 HO breaks down the heme porphyrin ring and cleaves the α-methene 
bridge, releasing carbon monoxide, biliverdin, and iron. Oxidation reaction 
between HO, NADPH-Cytochrome P450 reductase complex, and oxygen further 
converts biliverdin to bilirubin (catalysed by biliverdin reductase) and iron to 
ferritin (Ryter & Choi 2016; Wu & Wang 2005).  
Bilirubin is increasingly recognized as an antioxidant. For example, it has 
been shown that small amounts of bilirubin can protect neural cells from 
hydrogen peroxide oxidant in vitro (Baranano et al. 2002). There appears to be a 
correlation between low bilirubin levels and increased risk of coronary artery 
disease and myocardial infarction (Djoussé et al. 2003; Hopkins et al. 1996; 
Schwertner et al. 1994).  
The regulatory effects of HO-1 on iron levels have also been shown to 
prevent cell death by controlling intracellular iron levels (Ferris et al. 1999; Li & 
Stocker 2009). An in vitro study also demonstrated that ferritin itself might have 
endothelial antioxidant properties (Balla et al. 1992). 
HO-1, normally expressed at low levels, is upregulated in response to 
























Figure 1.7 Heme degradation pathway. Heme derived from hemoglobin is 
broken down into biliverdin, carbon monoxide (CO), and free iron 
(Fe2+) by heme oxygenase (HO). Biliverdin is then rapidly converted 
into bilirubin by biliverdin reductase (BVR).  












oxidative agents, stress, radiation, toxins, and ultraviolet light (Choi & Otterbein 
2002; Intagliata et al. 2019; Waza et al. 2018). Previously, stress-induced 
proteins have been shown to not only protect cells from immediate stress but 
also to fortify the organism to withstand future stresses originating from a 
different source. In the late 1980s, a 32kD mammalian stress protein, known as 
the heat shock protein-32 (HSP32), had been identified (Shibahara et al. 1987); it 
was later proven to be HO-1, the inducible form of HO (Keyse & Tyrrell 1989; 
Taketani et al. 1989). Benefits of HO-1 include anti-inflammatory properties, 
neuroprotection, and protective effects against cardiovascular, diabetic, hepatic, 
and renal diseases (Waza et al. 2018; Wu & Wang 2005).  
Although HO-2 is constitutively expressed and its gene expression 
remains fairly consistent under stress conditions, it also plays important roles in 
neuroprotection of the brain and neurologic disease; protection against 
cardiovascular, pulmonary, and renal diseases as well as diabetes; protection 
against male reproduction disease and pregnancy-related complications; 
protection against oxidative stress and deleterious effects of inflammation 
(Intagliata et al. 2019; Wu & Wang 2005). Studies of HO-2 knockout mice have 
demonstrated elevated levels of inflammatory cytokines, increased oxidative 
stress, and decreased healing potential (Bellner et al. 2009; Chen et al. 2018). 
The upregulation of HO has been extensively studied. While HO-1 is 
ubiquitously produced and found in virtually all tissues affected by stressors such 
as oxidative stress and inflammation, HO-2 is predominantly expressed in the 




Yachie et al. 1999). Current techniques involve the use of various protoporphyrin 
(Maines & Kappas 1977), adenoviral vector transfer of HO gene construct for 
short-term effects, and retroviral vectors for long-term upregulation (Abraham et 
al. 2007). Despite its potential, there are currently no clinical trials of HO 
upregulation gene therapy in humans and is currently not clinically feasible 
(Abraham et al. 2007; Kim et al. 2012; Luo et al. 2018; Motterlini & Foresti 2014). 
Therefore, the attention shifted towards the by-products of HO activity, notably 
carbon monoxide (CO). 
 
1.5.2 Carbon Monoxide 
CO is a diatomic molecule occurring naturally as a colourless and 
odourless gas (Ryter & Otterbein 2004). Although CO has a negative connotation 
due to CO poisoning, carbon monoxide plays a vital role in cell signalling, cellular 
communication, vasodilation, as well as peripheral and central nervous system 
neurotransmission (Kim et al. 2006). It also possesses anti-inflammatory, anti-
proliferative, and anti-apoptotic properties (Kim et al. 2006; Ryter & Otterbein 
2004; Weaver 2009).  
CO binds to hemoglobin to form carboxyhemoglobin (COHb). CO affinity 
for hemoglobin is nearly 200 times greater than that of oxygen (Weaver 2009). 
Exogenous inhalation of CO not only increases levels of COHb but also shifts the 
oxygen dissociation curve to the left, thus decreasing the ability of the remaining 
oxyhemoglobin to release its oxygen into the tissues (Ryter & Otterbein 2004). 




3% in non-smokers and less than 10% in smokers (Weaver 2009). Symptoms of 
CO intoxication include headache, visual disturbances, dizziness, nausea, 
fatigue, decreased dexterity, vomiting, seizures, coma, and death if left 
untreated. Although the onset of symptoms starts around COHb levels of 15% 
and progresses as the CO levels increase, CO intoxication becomes lethal 
around COHb levels of 50-60% (Bleecker 2015). Since oxygen and CO are direct 
competitors for hemoglobin binding, the mainstay of CO poisoning treatment is 
oxygen therapy, which can include both normobaric and hyperbaric oxygenation 
(Kim et al. 2006; Ryter & Otterbein 2004; Weaver 2009). 
The majority of endogenous CO is produced from heme metabolism. Daily 
production, in the absence of external stressors, reaches upwards of 10mL 
(Coburn et al. 1964). However, pathological conditions due to pro-inflammatory 
processes, external stressors, and environmental triggers that upregulate HO-1 
expression lead to an increase in endogenous CO concentration. Multiple animal 
studies have confirmed that upregulating HO-1 expression increases 
endogenous CO production, while HO inhibition decreases CO synthesis 
(Intagliata et al. 2019; Wu & Wang 2005). 
 
1.5.3 Effects of Carbon Monoxide 
 Multiple animal studies have demonstrated the benefits of exogenous CO 
application. CO therapy has shown inhibition of inflammatory mediators, 
decreased rates of apoptosis, decreased edema, and improved organ function in 




et al. 2003), and pigs (Lavitrano et al. 2004). Clinically, CO therapy has 
demonstrated improved graft healing, function, and survival following cardiac, 
intestinal, renal, and pulmonary transplantation (Akamatsu et al. 2004; Lavitrano 
et al. 2004; Nakao et al. 2003; Neto et al. 2004; Song et al. 2003; Zhang et al. 
2003). Exogenous CO application also appears to decrease hyperoxic and 
ventilator-induced pulmonary injuries, increases survival, and inhibits 
inflammatory cytokines and leukocytes (Dolinay et al. 2004; Otterbein et al. 
2003b). CO also decreased apoptosis and structural damage in mice with acute 
hepatic injury (Zuckerbraun et al. 2003). 
 
1.5.3.1 Cellular Signalling 
CO has a high binding affinity for heme proteins and transition metals, 
such as hemoglobin and myoglobin. Therefore, other potential hemoprotein 
targets include guanylate cyclase, cytochrome c oxidase, and cytochrome P450 
(Ryter & Choi 2016; Ryter & Otterbein 2004). 
CO appears to be a modulator of proteins with important implications on 
downstream smooth muscle relaxation, vasodilation, ion channel conductance, 
glycogenolysis, and cellular apoptosis (Morita et al. 1995; Motterlini & Otterbein 
2010; Ryter & Otterbein 2004). CO has been shown to modulate soluble 
guanylate cyclase (sGC) to produce cyclic guanosine monophosphate (cGMP). 
These have downstream effects on vasodilation and anti-proliferation. However, 




modulator of calcium- and voltage-gated potassium channels that are involved in 
vasoregulation (Peers 2011; Ryter & Choi 2016; Wang 1998).  
CO modulates signalling that controls inflammatory and apoptotic 
processes. It is an agonist to mitogen-activated protein kinases (MAPK) such as 
p38, c-Jun N-terminal kinases (JNK), and extracellular signal-regulated kinases 
(ERK), leading to downstream inhibition of pro-apoptotic cytokines such as TNF-
ɑ, although the exact role of JNK and ERK kinases need further elucidation 
(Ryter & Choi 2016; Ryter & Otterbein 2004; Zuckerbraun et al. 2007). Animal 
and in vitro studies have shown CO as a potential inhibitor of NADPH oxidase- 
and mitochondria-dependent ROS, as well as a modulator of iNOS (Nakahira et 
al. 2006; Ryter et al. 2007; Sarady et al. 2004; Zuckerbraun et al. 2007). 
 
1.5.3.2 Vasodilation 
 CO plays an important role in vasoregulation. Although NO is a much 
more potent sGC modulator (Ryter & Otterbein 2004), its effect on vascular 
smooth muscle cells appears to be independent of NO (Morita et al. 1995). 
Suematsu and colleagues (1994, 1995) demonstrated increased perfusion and 
vasorelaxation when either CO or cGMP was administered, whereas inhibition of 
cNOS and iNOS did not affect this response (Suematsu et al. 1994, 1995). CO 
may also have a role in promoting cGMP-independent vasodilation, controlling 
calcium-activated potassium ion channels, as illustrated by cerebral arteriolar 




that vasodilation is induced by both cGMP-dependent and calcium-activated 
potassium ion channel-dependent effects simultaneously (Wang et al. 1997). 
 
1.5.3.3 Anti-Apoptotic Effects 
Apoptosis, also known as programmed cell death, plays a vital role in 
maintaining cellular and tissue homeostasis under normal physiological state and 
disease conditions. It is characterized by cell shrinkage, pyknosis (chromatin 
condensation), karyorrhexis (fragmentation of the nucleus), and plasma 
membrane blebbing, which eventually breaks off into apoptotic bodies and are 
engulfed by phagocytes (Linkermann et al. 2013; Van Cruchten & Van den 
Broeck 2002). Its mechanism can be separated into extrinsic and intrinsic 
pathways. Both pathways lead to downstream caspase -3 and -9 release as well 
as proteolytic enzymes that induce cell death. In the extrinsic pathway, TNF-α 
induces the pro-apoptotic pathway by initiating death-inducing signalling complex 
(DISC), including Fas, Fas-associated death domain, and caspase-8, which 
ultimately activates caspase-3 activity. The intrinsic pathway, usually upregulated 
in response to irreparable intracellular and DNA damage, is activated through 
mitochondrial translocation of Bax protein from the Bcl-2 family, which then 
releases pro-apoptotic mediators such as cytochrome c and binds onto apoptotic 
protease activating factor-1 (APAF-1), thus triggering caspase activity (Bano & 
Prehn 2018; Green & Llambi 2015; Kluck et al. 1997; Soares et al. 2002; Wang 
et al. 2011; Zou et al. 1997). Various caspase-independent pathways lead to 




which leads to lysosomal-induced cell death. Calpain also functions as a 
cleavage system for apoptotic-inducing factors (AIF) causing DNA damage, while 
ROS stimulate AIF release through the activation of poly(ADP-ribose) 
polymerase-1 (Bano & Prehn 2018; Hongmei 2012; Kang et al. 2004; Kim et al. 
2018).  
Apoptosis is biologically distinct from cellular necrosis, also termed 
necroptosis. While TNF-α is a strong potentiator of both necroptosis and 
apoptosis, they have distinct pathways. In necroptosis, TNF-α mediates receptor-
interacting protein (RIP) activation forming the RIP-1/RIP-3 complex. Cell death 
is then induced by mixed lineage kinase domain-like protein phosphorylation 
leading to cell membrane damage (Linkermann & Green 2014; Liu et al. 2019a; 
Vanlangenakker et al. 2011a,b). 
Many studies have demonstrated that CO displays anti-apoptotic 
properties. Brouard et al. (2000) demonstrated the anti-apoptotic effects of CO, 
mediated through activation of p38 MAPK, in an in vitro murine model (Brouard 
et al. 2000). A murine model of pulmonary I-R injury also showed an inhibitory 
effect of CO on mitochondrial cytochrome c release (Zhang et al. 2003). 
Additional studies identified synergistic interaction between the HO-1/CO 
pathway, NF-κB-dependent anti-apoptotic genes (A1 and c-IAP2), and p38 
MAPK activation in preventing TNF-ɑ-mediated apoptosis (Brouard et al. 2002). 
It appears that the NF-κB transcription activity may have both pro- and anti-
apoptotic effects. While CO interacts with NF-κB sub-genes A1 and c-IAP2 to 




inflammatory agent through proteasome pathways and upregulation of 
inflammatory mediators via its promoter gene (Soares et al. 2002). Important 
components of cellular apoptosis involve caspases (family of protease enzymes), 
Fas and Bax proteins (Bcl-2 family), that have been shown to be inhibited by CO 
(Ryter & Choi 2016; Wang et al. 2011; Zhang et al. 2003).  
 
1.5.3.4 Anti-Proliferative Effects 
 The anti-proliferative effects of CO were examined by Morita et al. (1995). 
They demonstrated that, under hypoxic conditions, HO-1 and subsequent CO 
production significantly increased, leading to the upregulation of cGMP in 
vascular smooth muscle cells. The addition of CO inhibitors and CO scavengers 
completely inhibited this response. The cGMP produced in the vascular smooth 
muscles did not involve NO (Morita et al. 1995).  
The CO-cGMP pathway has been suggested to prevent vascular smooth 
muscle cell proliferation and intimal hyperplasia (Motterlini & Otterbein 2010; 
Ryter & Otterbein 2004). Otterbein et al. (2003) demonstrated CO-induced anti-
proliferative effects in rodent models, dependent on the activation of both cGMP 
and p38 MAPK (Otterbein et al. 2003a). 
 
1.5.3.5 Anti-Inflammatory Effects 
CO has been shown to exhibit anti-inflammatory effects, both in vitro and 
in vivo. In an in vitro model of sepsis, CO inhibited TNF-ɑ release, along with 




orthotopic lung transplant prevented severe intra-alveolar haemorrhage and 
intravascular coagulation (Song et al. 2003). CO was also found to significantly 
improve renal function, decrease pro-inflammatory cytokine expression and renal 
tubular injury, as well as inhibit tubular apoptosis in a kidney transplant model 
(Abe et al. 2017). Furthermore, CO has been shown to inhibit NADPH oxidase- 
and mitochondria-dependent ROS, while also downregulating NF-κB activity, 
thereby reducing TNF-ɑ-induced leukocyte-endothelial upregulation of E-selectin, 
ICAM-1, and VCAM-1 (Chhikara et al. 2009; Ferran et al. 1995; Ryter & Choi 
2016; Soares et al. 2002). 
 
1.5.4 Carbon Monoxide-Releasing Molecules 
To avoid the toxicity of CO inhalation, the development of carbon 
monoxide-releasing molecules (CO-RMs) was undertaken. CO-RMs are 
molecules capable of releasing CO on-demand, delivering it to the tissues 
without significant changes in COHb levels (Motterlini & Foresti 2014; Ryter & 
Choi 2016). 
The first CO-RMs were synthesized by Motterlini et al. (2002) (Table 1.1). 
CORM-1 ([Mn2(CO)10]), the first CO-RM produced, contains manganese at its 
centre and releases CO rapidly (Motterlini et al. 2002). However, it needs photo-
activation and, therefore, has limited use in vivo. CORM-2 contains ruthenium 
([Ru(CO3Cl2)]) and requires organic solvents to be dissolved via ligand 






Table 1.1. Most common carbon monoxide-releasing molecules (CO-
RMs). CORM-1 and CORM-2 release CO rapidly but are not water-
soluble. CORM-3 and CORM-A1 are water-soluble. 
 Adapted from Motterlini (2007). 
 
Name  Chemical Structure  Solubility CO Release 
 
CORM-1      DMSO Light-dependent 
Fast (t1/2<1min) 




CORM-2    DMSO Ligand substitution 
     Fast (t1/2=1min) 
     0.7M CO/mole CO-RM 
 
 
CORM-3      Water Ligand substitution 
        Fast (t1/2=1min) 




CORM-A1      Water pH dependent 
        Slow (t1/2=21min) 




CORM-F3      DMSO Metal oxidation 
        Slow (t1/2=55min) 







is a water-soluble version of CORM-2, also containing ruthenium. CORM-3 is a 
rapid equimolar CO releaser (within 10 minutes of being dissolved in water) and, 
thus, has a potential for clinical use (Motterlini et al. 2002; Wu & Wang 2005). 
At present, ruthenium does not appear to have any physiological function 
while being used as experimental anti-cancer drugs. Consequently, metal toxicity 
and DNA alteration remain a concern for human studies (Emsley 1989; Bergamo 
& Sava 2011). Alternative forms of CO-RMs that are, in theory, more 
physiologically friendly have been developed including CORM-A1 and CORM-
401. CORM-A1 ([Na2H3BCO2]) contains a boron-centric carboxylic group rather 
than a transition metal, allowing pH- and temperature-dependent CO release 
rather than ligand substitution. CORM-401 ([Mn(CO)4S2CNMe(CH2CO2H)]), in 
contrast, contains a manganese centre and releases 3 moles of CO per mole of 
CORM-401. Both forms of CO-RM are slower releasers of CO compared to 
CORM-3 with a half-life of approximately 21 minutes (Almeida et al. 2016; Fayad-
Kobeissi et al. 2016; Inoue et al. 2017; Motterlini et al. 2005). 
 
1.5.4.1 CORM-3 
Administration of CORM-3 has been shown to be beneficial in several 
animal models, ranging from aortic vasodilation (Foresti et al. 2004), cardiac 
inotropy (Musameh et al. 2009), anti-ischemic effects on renal tissue (Sandouka 
et al. 2006), acute liver failure (Yan et al. 2016), vasodilation in cirrhotic rats 




(Yabluchanskiy et al. 2012), and inhibition of leukocyte-derived MPO activity in 
vascular endothelial injury (Patterson et al. 2014).  
Sandouka et al. (2006) demonstrated improved reperfusion and 
glomerular filtration rate in I-R models of kidney transplant following treatment 
with CORM-3 (Sandouka et al. 2006). In a murine model of acute liver failure, 
CORM-3 significantly inhibited pro-inflammatory cytokines such as TNF-ɑ, IL-1β, 
IL-6, and increased IL-10 (an anti-inflammatory cytokine), while also inhibiting the 
expression of iNOS, Toll-like receptor-4, and NF-κB transcription activities (Yan 
et al. 2016). CORM-3 also displayed an anti-inflammatory effect in haemorrhagic 
stroke by inhibiting TNF-ɑ (Yabluchanskiy et al. 2012). In vitro experiments on 
the heart also demonstrated significant cardioprotection in I-R models when the 
heart was re-perfused with CORM-3 (Clark et al. 2003). Additionally, in an in vitro 
human vascular endothelial cell (HUVEC) model of inflammation, CORM-3 
significantly inhibited leukocyte-derived MPO activity (Patterson et al. 2014). 
MPO is a mediator of oxidative stress, important in the innate immune system. 
However, when excessive leukocytes are activated during severe inflammatory 
responses, stimulation of MPOs and subsequent ROS production contribute to 
vascular and organ dysfunction (Cepinskas et al. 2008; Patterson et al. 2014). 
Recently, CORM-3 has been found to show promise as a possible 
pharmacological agent in the treatment of ACS. In a rat model, the administration 
of CORM-3 at fasciotomy led to improved microvascular perfusion, significantly 
decreased tissue injury, and diminished tissue leukocyte activation (Lawendy et 




muscle injury but also significantly inhibited inflammation at both local and 
systemic levels. This was characterized by complete inhibition of systemic TNF-α 
release as well as suppression in oxidative bursts of leukocytes (Bihari et al. 
2018).  
To transition the promising results into human studies, Bihari et al. (2019) 
developed an in vitro model of ACS, using HUVEC stimulated with serum 
isolated from ACS patients. Incubation of HUVEC with ACS serum led to an 
endothelial barrier breakdown, an increase in oxidative stress and apoptosis, as 
well as polymorphonuclear leukocyte activation. The application of CORM-3 
offered significant protection against these detrimental effects (Bihari et al. 2019). 
 
1.6 PURPOSE OF THE THESIS 
If not treated promptly, ACS is a limb-threatening and often life-threatening 
condition. The current gold standard for treatment is surgical fasciotomy. While 
the pathophysiology of ACS is not entirely understood, it shares many similarities 
with I-R injury. Although it is generally accepted that irreversible tissue damage 
occurs around 6 to 8 hours, previous studies have demonstrated myonecrosis as 
early as 3 hours within the onset of ACS. 
The effects of complete ischemia (where the onset is known, as all 
circulation is cleanly cut off) and subsequent reperfusion injury have been 
extensively studied. Unlike complete ischemia, however, ACS occurs in the face 
of patent vessels; distal pulses are present in the majority of ACS patients, 




intact, while the microcirculation becomes dysfunctional. The diagnostic 
challenges become even greater, as ACS is a clinical diagnosis, and multiple risk 
factors can delay timely diagnosis. The onset of ACS in itself is often difficult to 
identify. 
Despite proposed non-operative alternatives in case reports or small case 
series, none have been proven to be an effective first-line treatment or a 
substitute for fasciotomy. Recently, the role of CO as a potential pharmacological 
therapeutic agent for the treatment of ACS has been explored. In preclinical 
studies, using both small (rat) and large (porcine) models of ACS, administration 
of CO, in the form of water-soluble CO donor, CORM-3, at fasciotomy has 
resulted in decreased microvascular perfusion deficits, diminished tissue injuries, 
blocked leukocyte activation, and inhibition of systemic TNF-α release (Bihari et 
al. 2018; Lawendy et al. 2014). 
The purpose of this thesis was to evaluate the effects of CO in ACS 
without fasciotomy, by investigating its short- and longer-term effects on 
microvascular dysfunction, myonecrosis, and inflammatory response. For this 
experiment, CORM-3 was chosen as the CO donor, given its water solubility and 
rapid CO release. We hypothesized that the administration of CORM-3 would 
produce a lasting beneficial effect. The ultimate goal is to identify whether CO 
can be used as a stand-alone first-line treatment of ACS, or at least extend the 
surgical window. For the purpose of this thesis, the terms ‘elevated ICP’ and 
‘ACS’ were used interchangeably. However, it is important to note that ACS is a 




CHAPTER 2: MATERIALS AND METHODS 
 
2.1 ANIMAL CARE 
The experimental protocol for the study was approved by the Animal Care 
Committee of the Canadian Council on Animal Care (CCAC) at the University of 
Western Ontario, London, Ontario, Canada. The daily animal care, handling, and 
housing conformed with the guidelines established by the CCAC. The rats were 
housed in pairs, in clear plastic cages, and under 12:12 light:dark cycle. They 
had access to food and water ad libitum. 
 
2.2 ANIMAL DESCRIPTION  
Twenty-nine male Wistar rats were used for this study. Their body weight 
ranged between 190g and 260g. 
 
2.3 CARBON MONOXIDE 
A water-soluble CO donor, carbon monoxide-releasing molecule-3 
(CORM-3) (tricarbonylchloro-glycinate-ruthenium(II), [Ru(CO)3Cl-glycinate]; 
molecular weight 295gmol-1), was used in this experiment. It was synthesized in 
our lab using previously published method (Clark et al. 2003). A stock solution of 
10mg/ml was prepared fresh, in isotonic saline, just before the injection. Each rat 
received 10mg/kg of CORM-3 intravenously, via the left lateral tail vein. 
Inactive CORM-3 (iCORM-3) was used as an inert control. iCORM-3 was 




allowed it to release all CO from the stock solution prior to administration to the 
animals. The lack of CO in iCORM-3 had been previously confirmed 
spectrophotometrically by myoglobin conversion assay (Bihari et al. 2017). 
 
2.4 EXPERIMENTAL SETUP 
2.4.1 General Overview 
 ACS was generated in the right hind limb of rats by elevating ICP under 
general anaesthesia. Elevated ICP was maintained at Δp <30mmHg (ICP value 
of 40-65mmHg) for 2 hours. Experimental drug injections were administered; 
animals were then allowed to recover. Adequate pain control was provided to all 
rats using buprenorphine (Buprenex 0.05mg/kg IM q8h). During the recovery 
period, the rats were housed individually to prevent identification errors and 
erratic social behaviour. 
Following the proper recovery time in accordance with the assigned 
experimental group (24, 48 or 72 hours), all rats were re-anaesthetised and 
intravital video microscopy (IVVM) was performed. At the conclusion of IVVM, 
animals were euthanized by cardiac puncture under the deepest plane of 
anaesthesia.  
Sham animals underwent all procedures, but the ICP remained at baseline 








Anaesthesia was carried out using inhalational isoflurane. Induction of 
general anaesthesia was achieved using 5% isoflurane in 100% oxygen gas at a 
flow rate of 2L/min. Anaesthesia was maintained using 2% isoflurane at a flow 
rate of 0.5L/min and adjusted as needed to maintain adequate anaesthetic depth. 
A digital rectal thermometer probe was used to monitor core body temperature. A 
heating lamp was used to maintain body temperature at 37°C. 
 
2.4.3 Acute Compartment Syndrome 
The experimental model was previously described by Lawendy et al. 
(2011). Briefly, ICP elevation was achieved by continuous infusion of isotonic 
saline solution into the anterior compartment of the hindlimb using a 24-gauge 
angiocatheter (BD, Franklin Lakes, NJ). An electronic compartmental pressure 
monitoring system (Synthes USA, Paoli PA) was inserted into the posterior 
compartment through a 14-gauge angiocatheter (BD, Franklin Lakes, NJ). Both 
the anterior and posterior compartments became isobaric as the pressures rose, 
which allowed ICP monitoring from the posterior compartment. Continuous saline 
infusion was administered through a gravity-feed system where the isotonic 
saline bag was placed 120cm above the infusion site (Figure 2.1). 
Elevated ICP was maintained between 40mmHg and 65 mmHg to achieve 
Δp between diastolic blood pressure and ICP of <30mmHg for two hours. It has 


















Figure 2.1  Schematic illustration of rat ACS experimental setup. Isotonic 
saline is continuously infused in the anterior compartment of the 
hind limb, maintaining elevated ICP between 40mmHg and 
65mmHg. An angiocatheter connected to an electronic 
compartmental pressure monitoring system is inserted in the 
posterior compartment.  






to about four hours in humans, given the metabolic differences (Hoppeler & 
Weibel 2005; Hulbert et al. 2007; Lawendy et al. 2011; Marquet et al. 2005); 
hence two hours of elevated ICP should be the equivalent of about eight hours in 
humans. 
 
2.5 EXPERIMENTAL GROUPS 
Rats were randomly assigned to one of four main groups: (1) sham, (2) 
ACS followed by 24 hour recovery, (3) ACS followed by 48 hour recovery, and 
(4) ACS followed by 72 hour recovery. Each group was further subdivided into 
animals that received CORM-3 or those receiving iCORM-3 injection. In this 
experiment, each rat received only a single dose of either CORM-3 or iCORM-3. 
 
2.5.1 Sham 
Six animals underwent all procedures, but the compartment pressure 
remained at baseline level of 0mmHg. Rats received an injection of CORM-3 
(n=3) or iCORM-3 (n=3), followed by IVVM. 
 
2.5.2 ACS with 24hr Recovery 
Eight rats underwent ACS, followed by IV administration of CORM-3 (N=4) 
or iCORM-3 (N=4). They were then allowed to recover for 24 hours, as described 
in section 2.4.1. Following the recovery period, animals were re-anaesthetised 





2.5.3 ACS with 48hr Recovery 
Seven animals underwent ACS, followed by CORM-3 (N=4) or iCORM-3 
(N=3) injection. They were then allowed to recover for 48 hours. Following 
recovery period, all animals were re-anaesthetised and underwent IVVM. 
 
2.5.4 ACS with 72hr Recovery 
Eight rats underwent ACS, followed by CORM-3 (N=4) or iCORM-3 (N=4) 
injection. They were then allowed to recover for 72 hours. Following recovery 
period, all animals were re-anaesthetised and underwent IVVM. 
 
2.6 INTRAVITAL VIDEO MICROSCOPY 
2.6.1 Muscle Preparation 
Under general anaesthesia, the extensor digitorum longus (EDL) muscle 
was prepared for IVVM using careful dissection and handling to avoid iatrogenic 
injuries. A lateral incision over the experimental hind limb was made. The 
underlying biceps femoris was exposed and incision through its fascial layer was 
undertaken, allowing retraction of the muscle. The tibialis anterior (TA), peroneus 
longus (PL), and lateral gastrocnemius (LG) muscles were then identified. 
Meticulous dissection was carried out to avoid traumatizing the saphenous vein 
and to maintain adequate hemostasis. Subsequently, the EDL was identified 
between TA and PL. The underside of TA and PL were gently brushed off and 




tendon identified over the ankle was ligated using 3-0 silk and severed as close 
as possible to the bony insertion site.  
Following EDL preparation, the rat was then carefully moved onto the 
stage of IVVM microscope; the EDL muscle belly was partially reflected anteriorly 
into the saline bath containing vital dyes and stabilized using the 3-0 silk ligature 
(Potter et al. 1993).  
 
2.6.2 Vital Dye Staining 
Two fluorescent dyes, ethidium bromide (EB) (Sigma Aldrich, 
Mississauga, ON) and bisbenzimide (BB) (Sigma Aldrich, Mississauga, ON) in 
concentrations of 5μg/ml each were added to the saline bath in which the EDL 
was placed on the microscope slide. Both dyes bind DNA, hence label cell nuclei. 
Due to its size and hydrophilic nature, EB does not penetrate intact cell 
membrane; therefore, it was used to label injured or dead cells (i.e. cells with 
compromised cellular membrane). BB, a lipophilic dye, is able to enter all cells, 
thus labelling the nuclei of all cells (Daly et al. 1992; Potter et al. 1995). Cellular 




Microscopy was used to assess microvascular perfusion, tissue injury, and 
leukocyte behaviour. Microvascular perfusion was assessed by recording five 




20x objective (final magnification 700x) for 60 seconds each. An additional 10 
seconds was recorded from the same fields of view under epifluorescence 
illumination using the proper filters for BB (excitation wavelength = 343nm, 
emission wavelength = 483 nm) and EB (excitation wavelength = 482 nm, 
emission wavelength = 610nm) in order to assess tissue injury. 
Leukocyte behaviour was assessed by transillumination in five randomly 
chosen post-capillary venules, with diameter of at least 20μm using 40x objective 
(final magnification 1400x) for 45 seconds each. 
All videos were saved into the computer using Adobe Premiere software 
for offline video analysis. 
 
2.7 OFFLINE VIDEO ANALYSIS 
2.7.1 Microvascular Perfusion 
Three equidistant parallel lines were drawn perpendicular to the capillary 
axis on the video monitor.  Microvascular perfusion was quantified by counting 
the number of continuously-perfused capillaries (CPC), intermittently-perfused 
capillaries (IPC), and non-perfused capillaries (NPC) crossing each line, based 
on red blood cell movement (Lawendy et al. 2014). The CPC, IPC, and NPC 
were expressed as a percentage of the total number of capillaries. 
 
2.7.2 Tissue Injury Analysis 
The ratio of EB-labelled cells to BB-labelled cells (EB/BB) was used to 




2.7.3 Analysis of Leukocytes 
Leukocyte behaviour was analyzed by counting the number of rolling and 
adherent leukocytes per 30 seconds in each venule. An adherent leukocyte was 
defined as a cell remaining stationary for at least 30 seconds, while a leukocyte 
was considered rolling if it remained in close contact with the vessel wall during 
its entire movement (Granger et al. 1989). The ImageJ software (NIH, Bethesda, 
MD) was used to measure the venular area. The results were expressed as the 
number of leukocytes per 30 seconds per 1000μm2 (Lawendy et al. 2011).  
 
2.8 STATISTICAL ANALYSIS 
All data were expressed as a mean ± standard error of the mean (SEM) 
and analysed using two-way analysis of variance (ANOVA) with Tukey multiple 
comparison post-hoc test. Data analysis was performed using Prism version 7.0c 
for Mac OS X (GraphPad Software Inc., San Diego, CA). The statistical 
significance was set at p<0.05. Minimum sample size calculation, based on 
leukocyte adhesion, was performed using StatMate (GraphPad Software Inc., 
San Diego, CA) with power set at 85%. We estimated that 48 rats were required 
to show a significant difference at an 85% confidence level. However, due to the 
COVID19 pandemic and circumstances out of our control, we were unable to 







CHAPTER 3:  RESULTS 
 
3.1 MICROVASCULAR PERFUSION 
3.1.1 Continuously-Perfused Capillaries  
ICP elevation led to a significant decrease in CPC, from 79±9% in the 
sham group, to 39±5%, 44±10%, 35±4% in the 24-, 48-, and 72-hour post-ACS 
groups, respectively (two-way ANOVA, p<0.0001). Administration of CO donor, 
CORM-3, resulted in significant increase in the number of CPC to 57±3%, 
61±3%, 53±7% at 24, 48, and 72 hours post-ACS, respectively versus 81±4% in 
sham (p=0.0042) (Figure 3.1). CORM-3 had no effect on the number of CPC in 
sham animals. 
 
3.1.2 Intermittently-Perfused Capillaries  
 In response to ACS, the number of IPC increased, from 10±6% in the 
sham group, to 27±10%, 26±5%, 30±5% at 24, 48, and 72 hours post-ICP 
elevation, respectively (two-way ANOVA, p=0.0365). Application of CORM-3 
resulted in 28±4%, 18±4%, 22±6% IPC at 24, 48, and 72 hours post-ACS, 
respectively versus 9±3% in sham (p=0.3474, n.s.) (Figure 3.1). CORM-3 






















Figure 3.1 The effect of CORM-3 on skeletal muscle perfusion following 
ACS. ACS resulted in a significant microvascular dysfunction; 
administration of CO donor, CORM-3, partially restored the 
perfusion. CPC: continuously perfused capillaries; IPC: 
intermittently perfused capillaries; NPC: non-perfused capillaries 





3.1.3 Non-Perfused Capillaries  
A significant increase in the number of NPC was observed, from 11±3% in 
the sham group, to 35±5%, 29±7%, 35±4% at 24, 48, and 72 hours post-ICP 
elevation, respectively (two-way ANOVA, p=0.0006). Administration of CORM-3 
led to a significant decrease in the number of NPC in all time-matched groups 
(16±2%, 20±1%, 25±3% at 24, 48, and 72 hours, respectively versus 11±3% in 
sham, p=0.0012) (Figure 3.1). CORM-3 did not produce any effect on the number 
of NPC in sham rats. 
 
3.2 TISSUE INJURY 
Significant tissue injury in ACS rats was observed: the EB/BB ratio of 
0.03±0.003 in the sham group rose to 0.31±0.08, 0.41±0.08, 0.40±0.1 at 24, 48, 
and 72 hours post-ICP elevation, respectively (two-way ANOVA, p=0.0004). 
Administration of iCORM-3 had no effect on tissue injury in any of the ACS 
animals, while CORM-3 significantly reduced the EB/BB ratio to 0.15±0.05, 
0.17±0.05, 0.20±0.04 at 24, 48, and 72 hours post-ICP elevation, respectively 
(two-way ANOVA, p=0.0013). Additionally, no significant difference was found 























Figure 3.2 The effect of CORM-3 on skeletal muscle tissue injury 
following ACS. ACS resulted in a significant increase in tissue 
injury; administration of CO donor, CORM-3, significantly reduced 






3.3 LEUKOCYTE BEHAVIOUR 
3.3.1 Leukocyte Rolling 
Significant increase in leukocyte rolling following ICP elevation was 
observed at 24 hours: from 4±2 leukocytes/30sec/1000μm2 in the sham group, to 
19±5 leukocytes/30sec/1000μm2 in the ACS group (p=0.0007).  At 48 and 72 
hours post-ACS, leukocyte rolling was 9±1 and 10±2 leukocytes/30sec/1000μm2, 
respectively; values which were not significantly different from the sham group 
(p=0.3603 and p=0.2749, respectively). Administration of CORM-3 resulted in a 
significant reduction in rolling leukocytes at 24 hours: 5±1 
leukocytes/30sec/1000μm2 versus 2±0 leukocytes/30sec/1000μm2 in sham 
(p=0.0013). In the 48- and 72-hour groups, leukocyte rolling was 10±3 and 10±3 
leukocytes/30sec/1000μm2, respectively, which were not significantly different 
from iCORM-3 groups (p=0.9998 and p=0.9999, respectively) (Figure 3.3). 
 
3.3.2 Leukocyte Adhesion 
 ICP elevation led to a significant increase in adherent leukocytes, from 
1±1 in the sham to 5.6±0.8, 8.2±2.4, 6.7±1.0 leukocytes/30sec/1000μm2 at 24, 
48, and 72 hours following ACS, respectively (two-way ANOVA, p=0.0059). 
Administration of CORM-3 significantly reduced leukocyte adhesion to 2±1, 1±0, 
3±1 leukocytes/30sec/1000μm2 at 24, 48, and 72 hours post-ICP elevation, 




















Figure 3.3 The effect of CORM-3 on leukocyte activation following ACS: 
leukocyte rolling. ACS led to a significant increase in leukocyte 
rolling; administration of CO donor, CORM-3, attenuated this 





















Figure 3.4 The effect of CORM-3 on leukocyte activation following ACS: 
leukocyte adhesion. ACS led to a significant increase in leukocyte 
adhesion; administration of CO donor, CORM-3 attenuated this 








CHAPTER 4: DISCUSSION 
 
4.1 OVERVIEW OF RESULTS 
ACS is a surgical emergency for which the gold standard treatment is 
open fasciotomy. However, ACS remains a clinical diagnosis with multiple risk 
factors that can lead to delayed or missed diagnosis. Consequently, delayed 
management of ACS can result in loss of limb function, systemic complications, 
and even death (Mortensen et al. 2020; Olson & Glasgow 2005; Pearse et al. 
2002; Via et al. 2015).  
Given the challenges of timely diagnosis and surgical intervention, many 
alternatives have been previously proposed. Yet, none have been proven as a 
stand-alone first line treatment. Furthermore, fasciotomies have their own set of 
issues and may also result in significant debilitating complications (Fitzgerald et 
al. 2000; McMillan et al. 2019; Schmidt 2017). Therefore, there is a need to 
develop alternative therapeutic interventions in the treatment of ACS, or at least, 
to prolong the surgical window. 
Over the last decade, CO has shown therapeutic potential in animal 
models of ACS when administered upon fasciotomy. However, its effects in ACS 
without fasciotomy are unknown. Therefore, the aim of this experimental project 
was to assess the use of CO, liberated from water-soluble CORM-3, in 






4.1.1 The Effect of ACS  
Although the true underlying pathophysiology of ACS remains elusive, 
there is mounting evidence that ischemic insult may be occurring concurrently 
with reperfusion injury, rather than a pure ischemic event followed by reperfusion 
syndrome. Reperfusion following ischemia causes oxidative stress and mediates 
oxygen-derived ROS, leading to cellular damage through lipid peroxidation, 
leukocyte-endothelial activation, upregulation of inflammatory mediators such as 
TNF-α and IL-1β working synergistically along with leukotrienes, thromboxane 
A2, prostaglandins, and platelet-activating factors, thus causing further 
microvascular dysfunction, changes in vascular permeability, cell death, tissue 
necrosis, soft tissue swelling, increased ICP, and potential systemic inflammatory 
responses (Cowled & Fitridge 2011; Gourgiotis et al. 2007; Grace 1994; 
Lawendy et al. 2014; Lutz et al. 2010; Soares et al. 2002; von Keudell et al. 
2015). 
 
4.1.1.1 Microvascular Changes 
Hindlimb ICP elevation resulted in a significant increase in non-perfused 
and intermittently-perfused capillaries, whereas the number of continuously-
perfused capillaries significantly decreased, leading to a low-flow ischemic state. 
These findings are consistent with previous studies of ACS assessing CPC, IPC, 
and NPC changes using IVVM in rat models, where microcirculatory deficits were 
found to occur by shifting continuous perfusion towards altered and/or absent 




previous canine study had also characterized ACS as an incomplete and 
maldistributed microvascular blood flow rather than complete ischemia 
(Sadasivan et al. 1997). 
The results corroborate with previous studies of I-R, showing early 
significant microcirculatory changes. Menger et al. (1992) used a hamster 
striated muscle I-R model, showing significant capillary hemodynamic changes at 
30 minutes and 2 hours following reperfusion, but very little changes between 2 
hours and 24 hours (Menger et al. 1992). In rat gracilis muscle I-R, Olivas et al. 
(2001) had demonstrated progressive microvascular dysfunction mainly within 
the first 7 hours of reperfusion. However, the magnitude of hypoperfusion saw 
very little change between 7 and 48 hours after reperfusion (Olivas et al. 2001). 
This suggests rapid and non-reversed microvascular dysfunction when left 
untreated, which was reflected in our study. However, given that ischemia occurs 
concurrently with reperfusion in ACS, the magnitude of perfusion deficits and 
timing of its deleterious effects likely differ from a pure I-R injury. 
The no-reflow phenomenon has been used to describe the failure of 
capillary reperfusion and has been described in previous cardiac (Schofer et al. 
1985), renal (Summers & Jamison 1971), epigastric free flap (May et al. 1978), 
and skeletal muscle (Blaisdell 2002) models of I-R. However, its underlying 
mechanism remains controversial. Debate still exist whether it is a consequence 
of ischemic muscle and cell death leading to non-perfused vessels, or whether 
the reperfusion injury ultimately shunts vascular perfusion. The aetiologies of the 




functional. Structural no-reflow implies vasoconstriction, microembolization, 
endothelial damage, and extravascular compression (interstitial edema) while the 
functional variant is a result of leukocyte, erythrocyte, and platelet aggregation, 
observed especially in the post-capillary venules (Blaisdell 2002; Durante & 
Camici 2015; Maksimenko & Turashev 2012; Niccoli et al. 2010).  
The no-reflow phenomenon can be appreciated in our study with the 
significant amount of NPC. In ACS, increased fluid extravasation from the 
vascular bed increases interstitial pressures leading to ICP elevation; this causes 
adjacent capillary lumen compression, progressive non-perfusion and ischemia 
(Gute et al. 1998; Lawendy et al. 2011). However, microcirculatory deficits are 
not only dependent on passive vasoconstriction secondary to increased 
interstitial pressure, but also on pro-inflammatory responses from reperfusion 
leading to vascular endothelial damage and tissue necrosis.  
 
4.1.1.2 Tissue Injury 
In low-flow ischemia, since there is still a degree of perfusion, reperfusion 
injury occurs concomitantly with ischemia rather than a no-flow ischemic event 
followed by reperfusion. Thus, parenchymal damage is likely caused by the 
perfusion deficits leading to hypoxemia, coupled with the ensuing inflammatory 
response (Bihari et al. 2017; Forbes et al. 1996; Gute et al. 1998; Lawendy et al. 
2011, 2014, 2015). Although controversial, it appears that reperfusion following 
partial ischemia or elevated ICP produces more severe tissue damage than after 




1985). However, in a murine I-R experiment, Conrad (2005) demonstrated 
significantly reduced tissue viability at 24 hours post-reperfusion following 
complete ischemia, despite having greater early inflammatory response from 
partial ischemia (Conrad et al. 2005). 
In our study, the EB/BB ratio significantly increased, indicating extensive 
tissue damage from elevated ICP at all examined time points. The EB/BB ratio 
appears to have plateaued at the 48-hour mark, showing slightly higher value 
than what was found in the 24-hour group, but minimal difference compared to 
the 72-hour time point. Comparatively, an I-R rat study performed by Olivas et al. 
(2001) demonstrated muscle necrosis worsening over the first 8 hours, followed 
by minimal changes to the damaged tissues between 8 and 48 hours of 
reperfusion (Olivas et al. 2001). 
Reperfusion injury is a major contributor to the pro-inflammatory response. 
In a study by Bihari et al. (2017), no-flow ischemia followed by reperfusion 
demonstrated significant increase in EB/BB staining during the 90-minute 
reperfusion interval. However, after 2 hours of ischemia and prior to reperfusion, 
it was still at nearly the same level as in the sham group, indicating that the 
maximum amount of tissue necrosis occurred during reperfusion, and not during 
ischemia alone. The results also correlated with the systemic TNF-α levels, 
where TNF-α sharply increased at the time of reperfusion (Bihari et al. 2017). 
Thus, the pro-inflammatory response and subsequent tissue damage re-enforces 





The assumption that ischemic insult and reperfusion injury are occurring 
simultaneously in ACS is based on previous studies demonstrating perpetual and 
recurrent local I-R events, free radical generation, and endothelial damages, 
especially in peripheral vascular diseases (PVD). Both ambulation and exercise, 
but not while at rest, can induce progressive reperfusion syndrome from chronic 
hypoperfusion in patients with PVD. Its clinical symptom is known as intermittent 
claudication and can eventually progress to critical limb ischemia (Ciuffetti et al. 
1991; Dopheide et al. 2013; Hickman et al. 1994). Similar mechanisms have 
been observed in the progression of non-healing chronic wounds (Mustoe et al. 
2006) and diabetic foot ulcers (Alavi et al. 2014).  
In our study, ICP elevation caused significant cellular injury and tissue 
damage. Historically, cellular necrosis was thought to be a form of unregulated 
cell death, as a consequence of disease process. However, there is increasing 
evidence that cellular necrosis is, in fact, mediated by defined (but not fully 
understood) molecular pathways, and is termed necroptosis. Although 
necroptosis shares upstream inflammatory mediators with apoptosis (eg. TNF-α), 
their downstream pathways are biologically distinct (Linkermann & Green 2014; 
Van Cruchten & Van den Broeck 2002; Vanlangenakker et al. 2011a,b). In I-R 
injuries, it appears that both necroptosis and apoptosis are involved in cell death. 
A combination of both apoptotic and necrotic cells has been found in I-R studies 
of rat gracilis muscles (Wang et al. 2008), murine gastrocnemius muscles (Tran 
et al. 2012), as well as other organs, including the brain (Degterev et al. 2005), 




(Fischer et al. 2000). Previous studies of ACS have shown significant systemic 
pro-inflammatory cytokine TNF-α elevation (Bihari et al. 2018; Lawendy et al. 
2014, 2016). Although it is impossible to differentiate cell death by necroptosis 
and apoptosis in this study, both pathways were likely involved, given that they 
are both potentiated by TNF-α. 
Leukocytes are a major contributor to tissue damage and muscle necrosis. 
Tissue damage appears to be mediated by inflammatory cytokines, such as TNF-
α and/or IL-1β (Donohoe et al. 2018; Lawendy et al. 2011). Sadasivan et al. 
(1997) had previously demonstrated significant reduction in microvascular injury 
and neutrophil infiltration in ACS under neutropenic conditions (Sadasivan et al. 
1997). In a rat model of ACS, Lawendy et al. (2015) compared ACS in 
leukopenic and normal rats. Leukopenia led to the suppression of leukocyte 
recruitment and no significant muscle tissue injury was observed. Meanwhile, 
leukopenia had no effect on perfusion deficits (Lawendy et al. 2015). This 
demonstrated that in ACS, ischemic insult also occurs distinctively from 
inflammatory-mediated damage. In our study, elevated ICP also led to leukocyte 
activation and was associated with significant tissue injury. 
 
4.1.1.3 Leukocyte Activation  
Leukocyte activation in response to elevated ICP showed significantly 
higher number of rolling leukocytes at 24 hours, but not at 48 or 72 hours. In fact, 
the number of rolling leukocytes trended towards normal in the latter 2 groups 




increase in leukocyte adhesion in post-capillary venules was observed at all time 
points, with peak levels occurring at 48 hours post-ICP elevation. 
The results corroborate with those of previous experiments examining the 
relationship between leukocytes and vascular endothelial inflammation. In a rat 
model of endotoxin-induced uveitis (EIU), Miyamoto et al. (1996) demonstrated 
peak numbers of rolling leukocytes between 12 and 24 hours (Miyamoto et al. 
1996). Another experiment had shown peak rolling leukocyte at 24 hours and 
returned to normal by 72 hours (Baatz et al. 1995). In a rat endotoxin-induced 
intestinal inflammation study, the peak number of rolling leukocytes was found 
between 6 and 12 hours, and subsequently trended towards control-group levels 
from 24 to 72 hours while the number of adherent leukocytes peaked at 24 hours 
before trending back down (Watanabe et al. 2018). A report of rat hindlimb 
allograft rejection found a significant increase in rolling leukocytes up to 24 hours 
post-transplantation. The number of rolling leukocytes continued to increase by 
72 hours, however, not significantly. Meanwhile, leukocyte adhesion continued to 
increase significantly between 24 and 72 hours (Ozer et al. 1999). 
The early peak in rolling leukocytes, combined with later increase in 
leukocyte adhesion can be explained by the leukocyte-endothelial activation 
sequence. The selectin receptors found on leukocytes (L-selectin), endothelium 
(E-selectin) and both the endothelium and platelets (P-selectin) act as mediators 
of leukocyte rolling behaviour.  In I-R injury, inflammatory cytokines, complement 
factors, and ROS activate selectins to initiate rolling leukocytes. P-selectins 




released within 30 minutes. Meanwhile, E-selectin is induced under 
transcriptional control, and will take several hours to reach its peak. Additionally, 
shedding of the constitutively expressed L-selectin is inversely proportional to 
leukocyte activation and works synergistically with P-selectins to stimulate rolling 
leukocytes. Loss of L-selectins is also associated with activation of MAC-1, 
important for later ICAM expression (Cowled & Fitridge 2011; Kurose et al. 1994; 
Ley et al. 2007; Panes & Granger 1998; Weibel & Palade 1964). 
E-selectin appears to return to baseline levels by 24 hours from onset of 
inflammatory stimulus, while P-selectin has been found to be upregulated for up 
to 24 hours and expressed for up to 48-72 hours following leukocyte cascade 
activation (Cowled & Fitridge 2011; Hallahan et al. 1996; Panes & Granger 
1998). In rat models, P-selectin was found to be maximally expressed up to 24 
hours following cerebral artery reperfusion (Suzuki et al. 1997) and P-selectin 
mRNA expression was upregulated up to 24 hours in retinal I-R (Nishijima et al. 
2004). In a pig model of inflammation, peak expression of E-selectin was found 
within the first few hours while returning to near baseline levels at 24 hours 
(Binns et al. 1996). Additionally, all 3 selectins interact with leukocytes via P-
selectin glycoprotein ligand-1 (PSGL-1). While P- and L-selectins seem to share 
similar binding configuration to PSGL-1, it differs with E-selectin (Somers 2000, 
Ley 2003). PSGL-1 binding with E-selectin appears to be transient compared to 
P-selectins (Ley & Kansas 2004; Vestweber & Blanks 1999).  
To initiate arrest and adhesion, CD11/CD18 neutrophilic αβ-integrin 




neutrophilic VLA-4 interacts with MADCAM-1 and VCAM-1 ligands. While VCAM-
1 and ICAM-1 peak expressions have been highly variable, ranging from 6 hours 
to 36 hours, these ligands are, nonetheless, highly expressed up to 48 hours 
post-activation (Cowled & Fitridge 2011; Eppihimer & Granger 1997; Hallahan et 
al. 1996; Langer & Chavakis 2009; Panes & Granger 1998). Therefore, the 
higher expression of selectins within the first 24 hours and early weaning help 
explain the initial surge in rolling leukocytes while adhesion endothelial factors 
usually have increased upregulation up to 48 hours post-activation, if not longer.  
Inflammatory cytokines and chemokines play a key role in leukocyte 
activation. In a rat model of ACS, Donohoe et al. (2018) identified 16 detectable 
systemic cytokines/chemokines, 6 of which were significantly upregulated 
following ICP elevation. These included pro-inflammatory cytokines TNF-α, IL-1β, 
along with chemokines growth-related oncogene-α (GROα), monocyte 
chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein-1α 
(MIP-1α). They also found increased levels of anti-inflammatory cytokine IL-10. 
Subsequently, administrating TNF-α neutralizing antibodies (NA) alone or TNF-α 
NA concurrently with IL-1β NA resulted in a significant decrease of leukocyte 
rolling, whereas giving IL-1β NA alone had no effects. Meanwhile TNF-α NA 
alone or combined with IL-1β NA produced significant reduction in leukocyte 
adhesion, while IL-1β NA alone only produced partial improvements (Donohoe et 
al. 2018). Although GROα, MCP-1, and MIP-1α were not tested against NA, they 
remain important mediators of pro-inflammatory response and leukocyte 




Deshmane et al. 2009; García-Bonilla et al. 2011; Maurer & von Stebut 2004; 
Menten et al. 2002; Ouyang & O’Garra 2019). Thus, identifying the exact roles 
and temporal activation of these cytokines/chemokines on rolling leukocytes 
would help elucidate the differences seen between the earlier and later time 
points in our study.  
 
4.1.2 Therapeutic Effects of CORM-3-Derived CO 
CO has been found to exhibit potent anti-inflammatory, anti-proliferative, 
anti-apoptotic, and vasodilatory effects. However, given the toxicity of inhaled 
CO, CO-RMs were synthesized in order to control CO delivery without elevating 
COHb levels (Guo et al. 2004; Lawendy et al. 2014; Motterlini & Otterbein 2010; 
Ryter & Choi 2016). 
 
4.1.2.1 Effects of CORM-3 on Microvascular Perfusion 
Systemic application of CORM-3 led to partial restoration of perfusion 
following ICP elevation: there was a significant increase in CPC and decrease in 
NPC. Microvascular perfusion remained relatively constant and unchanged 
between the 24-, 48-, and 72-hour groups. Although significant microvascular 
improvements were observed following treatment with CORM-3, the perfusion 
deficit still remained significant compared to the sham group. The results of this 
study are comparable with those of ACS treated with CORM-3 at fasciotomy: 
CORM-3 significantly restored the number of CPC and reduced the number of 




as well as in pure I-R injury (Bihari et al. 2017). However, these studies carried 
out microvascular analysis between 45 minutes and 3 hours following elevation 
of ICP, whereas we assessed longer-term results. 
CO has been shown to mediate vasodilation via sGC. In the endothelial 
cGMP-dependent pathway, CO is in fact a weaker agonist than NO (Kajimura et 
al. 2010). However, CO appears to mediate NO-independent cGMP in the 
vascular smooth muscle cells, preventing proliferation and intimal hyperplasia. 
CO also mediates cGMP-independent pathways by mediating calcium-
potentiated potassium membrane channels to induce vasodilation (Jaggar et al. 
2002; Motterlini & Otterbein 2010; Ryter & Choi 2016; Ryter & Otterbein 2004; 
Suematsu et al. 1995; Wang et al. 1997). 
NO also plays an important role in vasoregulation. Vasoconstriction is not 
only a result of passive changes from increased interstitial pressure and edema, 
but also due to a vasomotor component and autonomic dysfunction (Durante & 
Camici 2015; Nanobashvili et al. 2003). Pericytes in the microvascular wall act as 
contractile cells, activated by vasoactive hormones. Capillary dilatation from 
pericyte activity appears to be mediated by the NO/cGMP pathway (Bettaga et al. 
2015; Hall et al. 2014; Kelley et al. 1988; Nanobashvili et al. 2003; Sakagami et 
al. 2001). CORM-3 has been shown to stimulate NOS in the endothelium and 
activate cGMP pathway, while inhibiting NOS in the acetylcholine-induced 
endothelium-dependent relaxation (Alshehri et al. 2013). In our study, CORM-3 




phenomenon, which could be explained, at least in part, by interplay of 
vasodilatory effects of CO and NO. 
 
4.1.2.2 Effects of CORM-3 on Tissue Injury 
In our experiments, tissue injury was significantly reduced following 
administration of CORM-3. EB/BB ratio in our study ranged between 0.14-0.2, 
values that are slightly higher than those found previously, where CORM-3 was 
given at fasciotomy or upon reperfusion (Bihari et al. 2017; Lawendy et al. 2014). 
However, those results reflect tissue injury at very early time points (45 to 90 
minutes) compared to 24, 48, and 72 hours in our current study.  
Our results are consistent with those of others who had previously 
demonstrated that CORM-3 was capable of lessening cellular damage and 
increasing tissue survival, including decreased cardiac infarct size and muscle 
damage (Clark et al. 2003; Guo et al. 2004; Varadi et al. 2007), improved renal 
graft survival and mitigating parenchymal damage (Sandouka et al. 2006; Vera et 
al. 2005), and demonstrated antiapoptotic effects in lung I-R injuries (Zhang et al. 
2003). While the exact mechanisms of cellular protection are most likely related 
to the vasodilatory and anti-inflammatory properties, there is another possibility: 
inhibition of apoptosis. CO appears to target multiple layers of the pro-apoptotic 
pathways, including inhibition of cytochrome C oxidase and NADPH oxidase-
derived ROS (Boczkowski et al. 2006; Taillé et al. 2005; Zuckerbraun et al. 
2007), upregulation of NF-kB-dependent anti-apoptotic genes (A1 and c-IAP2) 




Brouard et al. 2002; Ryter et al. 2007; Soares et al. 2002; Zhang et al. 2003; 
Zuckerbraun et al. 2007). 
Leukocytes, particularly neutrophils, also appear to play a significant role 
in generating the observed endothelial damage. Activated neutrophils secrete 
MPO, leading to the formation of ROS and destruction of cellular membrane 
(Dejonckheere et al. 2011; Eltzschig & Eckle 2011; Hobeika et al. 2008; Lutz et 
al. 2010; Panes & Granger 1998). Application of CORM-3 was found to modulate 
polymorphonuclear (PMN)-induced ROS production, as well as mitigate cell 
surface levels of elastase in several in vitro models, with subsequent reduction in 
PMN rolling and adhesion along endothelial cells, thus decreasing endothelial 
dysfunction (Bihari et al. 2019; Mizuguchi et al. 2009; Patterson et al. 2014). It 
can be surmised that, although CO is not a free radical scavenger, it may have 
the ability to suppress the oxidative stress indirectly, by modulating the activity of 
redox enzymes, thereby minimizing the extent of endothelial injury. 
 
4.1.2.3 Effects of CO and CORM-3 on Leukocyte Activity  
In our study, leukocyte-endothelial activation appeared to be inhibited by 
CORM-3, as demonstrated by a significant reduction of adherent leukocytes at 
24-, 48-, and 72-hour time points. Surprisingly, rolling leukocytes were markedly 
reduced by CORM-3 only at 24 hour, but not at later times. 
Multiple studies have demonstrated anti-inflammatory properties of CO 
and its inhibitory effects on leukocyte activity. For example, animals with acute 




reduction of ICAM-1 and VCAM-1 adhesion molecules, inhibition of inflammatory 
cytokines TNF-α, IL-1β, and IL-6, as well as downregulation of NF-kB expression 
(Liu et al. 2019a,b). In intestinal and hepatic I-R models, CORM-2 diminished 
expression of TNF-α, NF-kB activity, leukocyte and endothelial adhesion 
molecules, as well as neutrophil infiltration (Katada et al. 2010; Wei et al. 2010). 
CO was found to inhibit a variety of inflammatory cytokines, including MCP-1, in 
a murine renal I-R (Ruan et al. 2014), while increasing anti-inflammatory cytokine 
IL-10 in a rat model of pancreatitis (Chen et al. 2010) and a murine model of 
acute liver failure (Yan et al. 2016). Various in vitro and in vivo experiments have 
shown that application of CORM-3 led to inhibition of TNF-α-mediated activation, 
translating into a decrease in VCAM-1, E-selectin, integrin complexes, as well as 
caspases (pro-apoptotic) activity (Bergstraesser et al. 2012; Bihari et al. 2019; 
Motterlini 2007; Song et al. 2009; Vadori et al. 2009). Additionally, CORM-3 has 
been shown to have cytoprotective effects in cardiac and renal I-R through 
upregulation of mitochondrial ATP-dependent potassium channels and calcium-
potentiated potassium channels, downregulation of NADPH oxidase-generating 
superoxide free radical, suppression of NF-kB activity, and inhibition of E-selectin 
and ICAM-1 (Caumartin et al. 2011; Clark et al. 2003; Guo et al. 2004). 
CO appears to suppress Toll-like receptor activity and NF-kB gene 
transduction pathways involved in inflammatory response. By inhibiting NF-kB 
activity, TNF-α-mediated upregulation of adhesion molecules (such as E-selectin, 
ICAM-1 and VCAM-1) is suppressed (Chhikara et al. 2009; Choi et al. 2017; 




lipopolysaccharide-induced upregulation of TNF-α and IL-1β (Otterbein et al. 
2000). Previous studies have demonstrated, in vitro, suppression of leukocyte-
endothelial interaction of platelet-activating factor, CD11b integrin surface levels, 
cell surface elastase (proteolytic enzyme), MMP activity and neutrophil-derived 
MPO activity; substantially decreasing adhesion and transmigration of leukocytes 
in inflammation-stimulated environments (Bihari et al. 2019; Inoue et al. 2017; 
Megías et al. 2007; Mizuguchi et al. 2009; Patterson et al. 2014; Urquhart et al. 
2007; Zhuang et al. 2017).  
 While CORM-3 appears to have a significant effect on leukocyte adhesion 
and transmigration, its effects on leukocyte rolling remains questioned. In our 
experiment, significant increase in rolling leukocytes occurred only at 24 hours, 
but not at 48 or 72 hours post-ICP elevation. This can be explained, at least in 
part, by selectin modulation and their differential PSGL-1 binding (Ley 2003; 
Somers et al. 2000; Vestweber & Blanks 1999). Previous studies of CO-RMs 
have shown suppression of the E-selectin receptors in renal rat I-R (Caumartin et 
al. 2011) and in vitro HUVEC models (Song et al. 2009). However, CORM-3’s 
effect on P-selectin remains largely unknown. A study of lipopolysaccharide-
stimulated platelet model using blood from healthy volunteers demonstrated a 
decrease in platelet P-selectin expression following CORM-2 treatment (Liu et al. 
2016). Given that CORM-3 attenuation of rolling leukocyte behaviour only 
occurred at 24 hours, its suppression is likely through the inhibitory effects of CO 
on inflammatory cytokines. However, CORM-3’s significant therapeutic effect on 




independent effect on adhesion molecules, such as immunoglobulin superfamily 
(eg. ICAM-1, VCAM-1) and αβ-integrin complexes (eg. LFA-1, MAC-1) (Bihari et 
al. 2017; Lawendy et al. 2014). Finally, uncovering temporal activation and 
effects of other inflammatory cytokines/chemokines on leukocytes, as well as 
their response to CORM-3 will help further elucidate the leukocyte activity 
observed in this study. 
 
4.2 STUDY LIMITATIONS 
Despite the encouraging results, there are several limitations to our study. 
First, the duration of elevated ICP was based on previous studies, as well as on 
physiological and mathematical assumptions (Hoppeler & Weibel 2005; Lawendy 
et al. 2011, 2014; Radermacher & Haouzi 2013). Therefore, it was assumed that 
2 hours of elevated ICP in rats corresponded to 8 hours in humans. However, 
future studies are required to correlate ACS equivalence in rats and humans.  
Second, only one injection of CORM-3 was administered, using a single 
route. Therefore, whether there is an additive or dynamic effect of multiple 
injections and/or injection sites, as well as the optimal rate of CO release in the 
treatment of ACS remain unclear.  
In this experiment, no functional testing (i.e. assessing rat hindlimb 
function) was performed. Thus, no clinical correlations could be made. Finally, 
while CORM-3 does not seem to elevate COHb levels in animal models, it has 
yet to be tested in humans. How CORM-3 injections translate in humans during 




4.3 FUTURE DIRECTIONS 
This study remains an early experimental study of CORM-3 without 
fasciotomy. Further studies are required to elucidate its role as a potential first-
line treatment in ACS or as an adjunct to prolong the surgical window. 
1) Analyze the effects of CORM-3 during shorter intervals, e.g. at 6- and 12-
hours post-elevation of ICP, to identify whether there are more prominent 
effects in the earlier stages.  
2) Compare outcomes using different injection doses and frequencies, as well 
as alternative routes of administration of CORM-3. 
3) Perform functional limb assessments to determine the clinical outcomes of 
CORM-3. 
4) Further studies are needed to clarify CORM-3’s mechanism of action and its 
effects on tissue regeneration. 
5) In previous animal studies of ACS, despite undergoing fasciotomies, 
inflammatory markers remained elevated systemically, often observed as a 
second hit phenomenon. Clinically, acute renal failure, rhabdomyolysis, 
systemic shock, and multiorgan dysfunction syndrome can occur despite 
fasciotomies. Although CORM-3 has shown its ability to suppress TNF-α and 
other inflammatory cytokines, it would be important to determine whether 
inhibition of systemic inflammatory cytokines can be sustained long-term 
when treated without fasciotomy (Bihari et al. 2017; Donaldson et al. 2014; 






 Multiple alternative therapies to surgical fasciotomy have been proposed 
in the treatment of ACS. However, none of them have been validated as a 
potential first-line treatment. While the exact underlying mechanism of CORM-3 
still needs further elucidation, it is likely that the CO released has multiple 
therapeutic molecular and cellular targets during ACS (Ryter & Otterbein 2004). 
In this study, CORM-3 without fasciotomy has demonstrated improved 
microvascular perfusion, diminished tissue injury, and mitigated leukocyte 
activation. Based on the current literature, it is plausible to assume that CORM-3 
played a major role in mediating vasodilation, reducing pro-inflammatory 
cytokines/chemokines and formation of ROS, thereby inhibiting leukocyte-
endothelial adhesion molecules. This study is a novel experiment demonstrating 
sustained therapeutic effects of CORM-3 without fasciotomy in the treatment of 
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APPENDIX I:  FASCIOTOMY TECHNIQUES 
 
Currently, the only gold standard in the treatment of ACS remains surgical 
fasciotomy. The goal is to provide immediate pressure relief and decreased 
compartmental pressures. By incising the skin and rigid fascia, this increases the 
volume of the muscle compartments, thereby reducing the pressure and 
restoring microvascular perfusion (Schmidt 2017). During fasciotomy, the 
muscles are assessed for colour, consistency, contractility, and perfusion. Any 
necrotic tissue should be debrided (Lawendy & Sanders 2010; von Keudell et al. 
2015). 
The lower leg and forearm are the most commonly affected locations in 
ACS (Elliott & Johnstone 2003). In the lower leg, the most frequently described 
techniques are the single-incision (lateral incision) technique or two-incision 
technique (lateral and medial incisions). A single incision with concomitant 
fibulectomy has been previously described (Kelly & Whitesides 1967). However, 
this technique has fallen out of favour given that both the two-incision and single 
incision without fibulectomy techniques provide adequate release without the 
morbidity of fibular removal, while this technique also places the peroneal 
vessels and superficial peroneal nerve at risk (Ebraheim et al. 2016; Lawendy & 
Sanders 2010). In the forearm, the volar and dorsal approaches are used to 






I.1 LOWER LEG FASCIOTOMY 
Although better visualisation of the soft tissues and neurovascular 
structures favours the two-incision technique, both approaches have yielded 
satisfactory results and demonstrated adequate 4-compartment release (Forsh & 
Wolinsky 2013; von Keudell et al. 2015). 
 
I.1.1 Single-Incision Fasciotomy 
 The patient is positioned supine on the operative table. A tourniquet is 
applied to the thigh but not insufflated, and the limb is freely prepped and draped. 
A bump is also placed under the hip. A single lateral incision along the fibula is 
made longitudinally extending from the fibular head and ends just proximally to 
the lateral malleolus. Anterior and posterior skin flaps are created; the anterior 
and lateral compartments are identified, and, using dissecting scissors, 
longitudinal fasciotomies are performed. It is essential to identify and protect the 
superficial peroneal nerve in the distal third of the leg piercing out of the fascia 
from the lateral compartment. Using the posterior flap created and while 
elevating the structures in the lateral compartment, the superficial posterior 
compartment is exposed, and the fascia is incised. Subsequently, the soleus 
ridge is identified, and the soleus muscle is detached from the fibula in order to 
expose the deep posterior compartment and decompress it. Subperiosteal 
dissection is performed around the posterior side of the fibula as well to 
decompress the deep posterior compartment (Forsh & Wolinsky 2013; Gourgiotis 




I.1.2 Two-Incision Fasciotomy 
 The patient is set up the same way as in the single-incision technique. A 
20-25cm longitudinal incision is performed midway between the fibula and tibial 
crest (Figure I.1). Anterior and posterior skin flaps are created, and the lateral 
intermuscular septum is identified. Fasciotomies of the anterior and lateral 
compartments in line with the tibialis anterior and fibular shaft, respectively, are 
performed. Care is taken to identify the superficial peroneal nerve piercing 
through the fascia of the lateral compartment in the distal third of the leg. 
Attention is then turned towards the medial aspect of the lower leg. A medially 
based longitudinal incision is made 2cm posterior to the medial aspect of the 
tibia. The skin is retracted posteriorly, the saphenous nerve and vein are 
identified and protected, the septum dividing the superficial and posterior 
compartments is identified and released, and the fascia overlying the 
gastrocnemius-soleus complex is released. An incision overlying the flexor 
digitorum longus is then made to access and decompress the deep posterior 
compartment. When the soleus bridge is extended more than halfway down the 
tibia, its extended origin is also released in order to access the deep posterior 
compartment. (Forsh & Wolinsky 2013; Gourgiotis et al. 2007; Lawendy & 
Sanders 2010). For both techniques, the wound is left open with packing or loose 
skin closure for later primary closure or skin grafting. The leg is splinted with the 
foot plantigrade (Lawendy & Sanders 2010; von Keudell et al. 2015). 
 

















Figure I.1. Two-incision fasciotomy. The lateral incision is centred halfway 
between the fibular shaft and the crest of the tibia. Lateral 
intermuscular septum is exposed. The anterior compartment is 
released in line with the tibialis anterior while the lateral 
compartment is released in line with fibular shaft. A medial 
longitudinal incision 2cm posterior to the posterior margin of the 
tibia is created; gastrocnemius-soleus complex fascia is released 
followed by deep posterior compartment release via fascial incision 
over the flexor digitorum longus.  




I.2 FOREARM FASCIOTOMY 
I.2.1 Volar Approach 
The volar incision is performed using either a radial or ulnar curvilinear 
incision. Regardless of the choice of incision, the volar incision must begin 
proximal to the elbow flexion crease and terminate past the wrist crease (Figure 
I.2). Incisions at the elbow and wrist flexion crease are made at an oblique angle 
to avoid contracture. Proximally, the lacertus fibrosis is released and the brachial 
artery is explored. The mobile wad, flexor carpi ulnaris and its neurovascular 
bundle, flexor digitorum superficialis, and median nerve are decompressed, 
explored, and retracted. The fascia and epimysium overlying the flexor digitorum 
profundus are then incised. Distally, the carpal tunnel is always released during 
forearm fasciotomy. A distal volar ulnar approach to explore Guyon’s canal may 
be used when the ulnar nerve is affected (Forsh & Wolinsky 2013; Lawendy & 
Sanders 2010).  
 
I.2.2 Dorsal Approach 
Typically, a volar approach alone is sufficiently adequate to decompress 
the forearm. Nonetheless, posterior compartment pressures must be assessed. If 
needed, a dorsal incision extending from 2cm distal to the lateral epicondyle to 
the centre of the wrist at the level of the radioulnar joint is made for the posterior 
forearm. Subsequently, the fascia overlying the extensor retinaculum and the 




















Figure I.2 Fasciotomy of the forearm. A volar curvilinear incision is 
performed, the superficial volar compartment is then released by 
identifying the mobile wad, flexor digitorum superficialis, flexor carpi 
ulnaris, and median nerve. Then, the flexor digitorum profundus in 
the deep compartment is exposed by incising the fascia 
longitudinally. Proximally, the lacertus fibrosis is released while 
distally, the carpal tunnel is decompressed. 




released. The incision(s) are kept open with moist gauze for later primary closure 
or skin grafting, and the arm is splinted with the elbow below 90 degrees of 
























APPENDIX II:  PERMISSIONS TO USE COPYRIGHTED MATERIALS 
 
II.1 Operative Techniques: Orthopaedic Trauma Surgery 2010; 























II.2 Mechanisms of Vascular Disease: A Reference Book for Vascular 
Specialists (2011) 







































































Name:     Patrick Qi Wang 
 
Post-secondary    Champlain Regional College, 
Education and    Lennoxville, Quebec, Canada 
Degrees:    2010-2012 Diploma-Collegial Studies (Quebec) 
 
     McGill University 
     Montreal, Quebec, Canada 
     2012-2013 Med-P 
 
     McGill University 
     Montreal, Quebec, Canada 
     2013-2017 MDCM 
    
     University of Western Ontario 
     London, Ontario, Canada 
     2019-2020 MSc  
 
     University of Western Ontario 
     London, Ontario, Canada 
     2017-2022 FRCSC 
 
Honours and Awards:  Orthopaedic Trauma Association  
Resident Research Grant 
2020 – 2021 
 
Related Work Experience: Research Assistant 
     2019 – 2020 
      
Publications: 
 
Wang P, Matache B, Suh N, Grewal R. Treatment of Stages IIIA and IIIB in 
Kienbock’s Disease: A Systematic Review. Journal of Wrist Surgery, accepted 
July 14, 2020. 
 
Wang P, Lawendy AR, Schemitsch E, Bihari A. Possible therapeutic application 
of CORM-3-derived carbon monoxide in acute limb compartment syndrome. 
Orthopaedic Trauma Association, Annual meeting, October 2020. 
 
 
 
